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Executive Summary 
 
 
Biopharming – the production of pharmaceutical compounds in plant and animal tissue in 
agricultural systems – is touted as the next major development in both farming and 
pharmaceutical production. Biopharming represents new territory for both the agricultural and 
pharmaceutical industries, and presents novel challenges for government regulators. It 
presents both opportunities and challenges for the New Zealand economy. It is thus important 
to understand the current situation regarding biopharming and to assess the future directions 
and potentials of the industry. 
The food, agricultural and tourism sectors in New Zealand are economically significant, 
contributing around 27 per cent of GDP. They are also export-focused industries therefore the 
reactions of overseas consumers are important. New Zealand and overseas research suggests 
that agricultural biotechnologies like biopharming can contribute to economic growth, but 
also may risk negative reactions if the technologies are not accepted by consumers. For 
example, biopharming currently uses genetic modification, so the experience with that 
technology may be instructive. 
Production of a food or pharmaceutical compound can be viewed as a bundle of 
characteristics or a vector of dimensions, including technical issues of production, applicable 
regulations, political concerns, and consumer responses to the product. The literature indicates 
that biopharming differs from existing production methods in a large number of ways. The 
extent of the differences is generally unknown or known qualitatively. The analysis presented 
here suggests that not only are the sizes of the difference unknown, but their potential 
contributions to either costs or benefits are also unknown. Analyses that project future 
financial benefits from biopharming tend, on the other hand, to assume that technical, 
regulatory, political, and consumer issues are resolved. 
From the academic literature, this report derives an economic model or framework for 
considering biopharming. This model is based on a cost-benefit approach to valuing changes 
in products and production methods. The model indicates the product dimensions that are 
likely to be affected by biopharming methods and how these dimensions may affect the costs 
and benefits of production. It also identifies the uncertainties in existing analyses. Finally, it 
demonstrates a method by which careful analysis of the economic costs and benefits of 
biopharming could proceed. 
Two potential products are discussed using this model: recombinant human lactoferrin (rhLF) 
produced in cow’s milk and low-GI potatoes. The analysis of rhLF suggests several things. 
First, all the necessary business information to assess the economic potential of producing 
recombinant human lactoferrin in milk in New Zealand is not available. Any assessment at 
this stage is necessarily preliminary. Secondly, it will be difficult to earn more than an 
economically normal profit by developing and marketing rhLF. There seem to be several 
close substitutes and competing technologies, so there appears to be little opportunity to 
create a dominant position in the market and earn oligopoly or monopoly profits. Finally, 
social science research suggests that introducing a GMO into the New Zealand dairy sector 
has a potential to cause a minimum of NZ$539.6 million in losses to the dairy and tourism 
industries. Thus, such a biopharming endeavour would need to offset those losses before it 
could be viewed as a net positive for the New Zealand economy. Given that worldwide sales 
of lactoferrin are currently in the tens of millions of US dollars, offsetting hundreds of 
millions of NZ dollars of lost exports seems unlikely in the short to medium term. 
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By contrast, the low-GI potato could have clear consumer appeal in the functional foods 
market, a multibillion dollar and expanding market segment. As a functional food, it would 
have lower regulatory hurdles than a biopharmaceutical. Furthermore, potatoes are a 
commonly consumed food, and the total market is again a multi-billion dollar market. A final 
positive factor is that New Zealand has scientific expertise in the area and business experience 
in creating profits from Plant Variety Rights. However, the genetically modified status of the 
product could create problems in some markets, and there is the risk of losing at least 
NZ$191.1 million in annual tourism earnings. It is unknown at this point what competing 
products would be developed, other types of low-GI potatoes, other low-GI foods, and even 
other dietary trends. 
Thus, the economic potential of these products varies tremendously, depending on the overall 
size of the potential market, control of technology or proprietary information, and other 
factors. However, it is clearly early days for these products. The future impact of consumer 
concerns is unknown and contested. The regulatory regime and practices needed to segregate 
novel products from other food have not been set up and are untested. The potential 
contributions to cost savings or other benefits of the technology have not been quantified. 
This is a preliminary piece of research. As more information becomes available on the 
potential products, the economics of their production, and consumer demand for them, future 
research will be able to improve the estimates of the economic impacts of biopharming in 
New Zealand. 
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Chapter 1 
Introduction 
 
 
Biopharming – the production of pharmaceutical compounds in plant and animal tissue in 
agricultural systems – is touted as the next major development in both farming and 
pharmaceutical production. For farmers, the appeal of biopharming is the production of high-
value, niche products, which moves them away from commodity agriculture. For 
pharmaceutical firms, biopharming promises a method for reducing production costs. For the 
general public, the benefits of biopharming would be cheaper drugs produced more quickly. 
Biopharming is new territory for the agricultural and pharmaceutical industries, and presents 
novel challenges for government regulators and others, particularly in New Zealand. This 
report examines the economics of the opportunities and challenges that biopharming presents. 
It investigates the research that has been done to this point in order to identify the key 
economic issues facing the development of biopharming. It also analyses the potential 
impacts, using a combination of economic theory and prior research. The result is an initial 
map that can help in charting New Zealand’s way in this new territory. 
The economic research on biopharming has two tasks. The first is to understand the current 
situation regarding biopharming. The second is to assess the future directions and potentials 
of the industry, to suggest what may happen and how the industry may develop. Both of these 
tasks are addressed in this report. 
2  
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Chapter 2 
Prior Research 
 
 
2.1 Introduction 
This chapter focuses on prior research that can help in understanding the potential impacts of 
biopharming in New Zealand. Because biopharming has arisen out of a confluence of 
agriculture, pharmaceutical production, and biotechnology, a number of topics need to be 
included in a review of prior research. This chapter first examines the literature that focuses 
specifically on biopharming. This examination considers the state of the industry and the 
economic issues that arise with biopharming. These issues then serve as departure points for 
several subsequent sections, which include the economy of New Zealand, potential economic 
impacts of genetically modified organisms (GMOs) in New Zealand, overseas research on 
GMOs, and consumer literature relevant to the economics of biopharming. Finally, the 
potential uses of the technology range from functional foods – food products enhanced to 
provide health benefits – to nutraceuticals – biologically produced compounds intended for 
sale as supplements – to biopharmaceuticals – compounds that have gone through the full 
drug testing regime. 
 
2.2 Research on biopharming 
2.2.1 Introduction 
Whether the topic is the present or the future, it is very important to be precise when 
discussing biopharming. One necessary distinction is between actual and potential results. 
While much discussion focuses on the potential contribution that could result from successful 
production of pharmaceuticals in plants, the actuality is that this potential has not yet been 
realised. It is also necessary to distinguish amongst the different sectors being referred to in 
industry figures. Biopharming, in which compounds are produced in crops or livestock, is one 
part of a larger industry producing biological compounds. Biological compounds may also be 
produced through other technologies, such as cellular fermentation. A third distinction focuses 
on the risks and benefits of the technology: it is important to understand not only the size of 
the risks and benefits, but also who bears the risk and captures the benefits.  
 
2.2.2 Current situation 
The current situation in the biopharming industry is difficult to assess. It is a developing 
industry with a large number of companies entering and exiting. There is nearly no academic 
literature focused specifically on this industry, either on its structure or its technology. As a 
result, the economic information comes largely from two sources: the non-academic press and 
economic information contained in non-economic publications. 
Biopharming is one area of a larger industry focused on producing biological compounds of 
pharmaceutical interest. In biopharming, these compounds are produced using crop plants or 
livestock. The plants and animals are genetically modified to produce or express the 
compounds. The expression may happen in any or all parts of an organism: for example, a 
maize plant may be modified to express the compound specifically in seeds, or a cow to 
express the compound in milk. The site of the expression is a key issue, because it affects the 
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costs of production as well as the risks. Thus, tobacco has been pursued as a biopharm crop 
when expression is in leaf tissue because tobacco produces a large amount of green matter, 
while maize is useful for compounds produced in seed. 
These same compounds may be produced using other non-biopharming technology, however. 
In fact, according to Elbehri (2005) there are 84 biopharmaceuticals on the market, while 
Goldstein & Thomas (2004) stated that ‘during the last two decades, approximately 95 
biopharmaceutical products have been approved by one or more regulatory agencies for the 
treatment of various human diseases including diabetes mellitus, growth disorders, 
neurological and genetic maladies, inflammatory conditions, and blood dyscrasias’. All of 
these biologics, except perhaps one, are produced using non biopharming methods. Instead, 
they are produced using cell culture, in which vats of modified mammalian or plant cells are 
grown in containment and are then processed to extract the target compound. There is 
reference in the literature to one biopharmaceutical being produced using plant biopharming: 
the compound hirudin, produced in Canada (Giddings, Allison, Brooks, & Carter, 2000). The 
biopharmaceutical industry output is estimated to have a cumulative market value of $41 
billion, excluding pharma crop processes, with an annual growth rate of 20 per cent (Wisner, 
2005b). Graff & Moschini (2004) suggested that global sales of therapeutic proteins are $30 
billion with sales estimated to approach $60 billion by 2010. The market for industrial 
enzymes will be at about $2 billion and growing at five per cent per year. Finally, biological 
compounds such as the above are just one part of the much larger pharmaceutical industry. 
Biopharming differs from cell culture methods on several dimensions. The main differences 
are summarised in Table 11. This table appears to originate with Fischer & Emans (2000), but 
has been modified and repeated in a number of publications (Goldstein & Thomas, 2004; 
Kermode, 2006; Ma, Drake, & Christou, 2003; Stoger et al., 2002). The entries in the table 
indicate that biopharming is better than cell cultures in these ways: storage and distribution is 
easier and cheaper; gene size is not limited; it has multimeric protein assembly (SigA); 
production cost is lower; production scale is greater; propagation is easier; protein 
homogeneity may be higher; protein yield is slightly higher; biopharming is safer; scale-up 
costs are lower; and less time is required. However, there are issues that make biopharming 
less attractive than mammalian cell culture: there is a public perception that it entails greater 
risk; its glycosylation may not be correct; proteins may not fold accurately in transgenic 
plants; and therapeutic risks from the compounds is unknown. 
Looking at this list, the dimensions that appear to be driving the interest in biopharming are 
largely related to the costs of producing these therapeutic proteins. The widely-cited estimate 
from Kusnadi, Nikolov, & Howard (1997) is that plant biopharming could produce 
compounds at one tenth to one fiftieth the cost of currently methods. The range of cost 
comparisons for producing pharmaceutical compounds with different technologies is 
presented in Table 2 (which extends over two pages). These cost savings are a result of lower 
costs for the factories that produce the feedstock and purify the compounds. Cellular 
fermentation facilities require an investment of around $450 million and a time commitment 
of five to seven years for plant approval and construction, while the purification facilities 
required for plant biopharming would cost only $80 million and require three to five years to 
finish (Elbehri, 2005). Related to the lower cost is the greater convenience of scaling 
production up or down. With biopharming, more feedstock for the purification can be 
                                                 
1 The information in the table is repeated here without critical assessment. That is, the authors of the present 
economic report do not pretend to have the expertise to assess whether, for example, the protein folding in crop 
plants is different than protein folding in mammalian cell culture, or one method is ‘safer’ than another. Each of 
these dimensions could be further discussed, researched, and contested. The information is presented here in 
order to highlight that the literature on biopharming suggests that the differences between different methods of 
producing commercial biologic compounds are many and complex. 
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Table 1: Comparison of features of recombinant protein production in plants, animals, yeast and classical systems 
 Transgenic 
Plants 
Plant 
Viruses 
Yeast Bacteria Mammalian 
Cell cultures 
Transgenic 
Animals 
Cost/storage Cheap/RT Cheap/-20ºC Cheap/-20ºC Cheap/-20ºC Expensive/N2 Expensive 
Distribution Easy Easy Feasible Feasible Difficult Difficult 
Gene size Not limited Limited Unknown Unknown Limited Limited 
Glycosylation ‘Correct’? ‘Correct’? Incorrect Absent ‘Correct’ ‘Correct’ 
Multimeric protein assembly (SIgA) Yes No No No No Yes 
Production cost Low Low Medium Medium High High 
Production scale Worldwide Worldwide Limited Limited Limited Limited 
Production vehicle Yes Yes Yes Yes Yes Yes 
Propagation Easy Feasible Easy Easy Hard Feasible 
Protein folding accuracy High? High? Medium Low High High 
Protein homogeneity High? Medium Medium Low Medium Low 
Protein yield High Very high High Medium Medium-high High 
Public perception of ‘risk’ High High Medium Low Medium High 
Safety High High Unknown Low Medium High 
Scale up costs Low Low High** High** High** High 
 (unlimited biomass)     
Therapeutic risk* Unknown Unknown Unknown Yes Yes Yes 
Time required Medium Low Medium Low High High 
* - residual viral sequences, oncogenes, endotoxins; ** - large, expensive fermenters etc; ? – unclear. 
Source: (Fischer & Emans, 2000). 
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Table 2: Cost estimates for producing pharmaceutical compounds with different technologies 
Production method Cost Per Gram Comment Source 
Transgenic plant biopharming   
IgG from alfalfa grown 
in a 250m2 greenhouse 
US$500 - 600 Expression levels will have a significant impact on the costs but, at the best 
expression level reported [500 μg g−1 leaf for a secretory IgA] , the final cost should 
be well below US$50 g−1. The biggest component of cost with plantibodies will be 
purification. 
Assumed purification costs equivalent to industry costs for mammalian cell culture 
system. 
(Daniell, Streatfield, & 
Wycoff, 2001) 
Alfalfa leaves  
 
US$5.50a Cost based on commodity price of biomass and percentage of protein in the biomass, 
and assumed that 10% of total protein would be the target protein/compound. 
(Kusnadi et al, 1997) 
Canola 
 
US$8.95 a Cost based on commodity price of biomass and percentage of protein in the biomass, 
and assumed that 10% of total protein would be the target protein/compound. 
(Kusnadi et al., 1997) 
Corn  
 
US$8.10 a Cost based on commodity price of biomass and percentage of protein in the biomass, 
and assumed that 10% of total protein would be the target protein/compound. 
(Kusnadi et al., 1997) 
Peanuts  
 
US$26.40 a Cost based on commodity price of biomass and percentage of protein in the biomass, 
and assumed that 10% of total protein would be the target protein/compound. 
(Kusnadi et al., 1997) 
Pharmaceutical corn US$80 - 250 Depending on scale; Fernandez et al., 2002. (Elbehri, 2005) 
Potato  US$59.40 a Cost based on commodity price of biomass and percentage of protein in the biomass, 
and assumed that 10% of total protein would be the target protein/compound. 
(Kusnadi et al., 1997) 
Soybeans  
 
US$4.95 a Cost based on commodity price of biomass and percentage of protein in the biomass, 
and assumed that 10% of total protein would be the target protein/compound. 
(Kusnadi et al., 1997) 
Sunflower  
 
US$8.10 a Cost based on commodity price of biomass and percentage of protein in the biomass, 
and assumed that 10% of total protein would be the target protein/compound. 
(Kusnadi et al., 1997) 
Transgenic plants US$13 - 14 Cost of growing protein. (Drabenstott, 2002) 
Transgenic plants (incl. 
potatoes) 
US$10 - 20 Applications: Cholera vaccine (tobacco; Chlorogen, Inc); gastric lipase (corn; 
Meristem); hepatitis B. 
(Elbehri, 2005) 
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Production method Cost Per Gram Comment Source 
Transgenic animal biopharming    
Transgenic animal 
production systems  
US$100  (Daniell et al., 2001) 
Transgenic animals US$23 - 25 Cost of growing protein. 
 
(Drabenstott, 2002) 
Transgenic animals.  US$20 - 50 Applications: Lipase (sheep, rabbits; PPL Therapeutics); growth hormone (goats; 
Genzyme); factor VIII (cattle). 
(Elbehri, 2005) 
Cell culture    
Cell culture  US$1000  (Daniell et al., 2001) 
Hybridoma produced 
antibody 
US$5000  (Daniell et al., 2001) 
Lab US$50 - 100 Cost of growing protein. (Drabenstott, 2002) 
Mammalian cell culture US$350 - 1,200 Depending on scale; Fernandez et al., 2002. (Elbehri, 2005) 
Mammalian cells US$500 - 5000 Applications: Tissue plasminogen activator; factor VII (glycoprotein); monoclonal 
antibodies (Hercepin). 
(Elbehri, 2005) 
Therapeutic production 
of antibody with animal 
cell bioreactors 
US$106 - 650 Based on estimates from industry. (Morrow, 2002 in Elbehri, 
2005) 
Other    
Yeast 
 
US$50 - 100 Applications: beer fermentation; recombinant vaccines; hepatitis B viral vaccine; 
human insulin. 
(Elbehri, 2005) 
a. Actual figures in Kusnadi et al. (1997) indicated these prices as per kilogram. However, such prices are inconsistent with a fall in production costs to one-twentieth to  
one-fiftieth current levels. For example, Datar & Rosen (1990) gave a cost of production using fermenter technology at $50 per gram, or $50,000 per kilogram, while 
Petridis, Sapidou, & Calandranis (1995) conducted a profitability analysis based on $110,000 per kilogram. Thus, prices from Kusnadi et al. are given here as per gram. 
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produced by growing more plants or animals, and creating more purification facilities is 
cheaper and less time consuming. Thus, creating more or less of a compound is easier than 
with current methods.  
Whether this cost comparison describes the actual situation or rather biopharming’s potential 
is unclear. The comparison has been repeated in one form or another in a variety of 
publications. However, commercial plant biopharming is not a current reality (again, with one 
exception), so there is likely to be an element of speculation in these figures. The one 
comparison of actual costs that was available for this research was that biotech company 
Agennix claimed that it could produce lactoferrin using cell culture methods at a cost 
comparable to Ventria Bioscience’s biopharmed rice (Wisner, 2005b). 
A further point raised in the above comparison of production methods is that the compounds 
produced through biopharming, in particular plant biopharming, are not exactly like those 
produced in cell culture/fermentation. These cost calculations, therefore, appear to presume 
that the technical issues facing biopharming, such as glycosylation or protein folding, have 
been overcome. The cost calculations indicating large cost savings through plant biopharming 
are in effect comparing the costs of producing two different compounds. This idea will be 
formulated more explicitly below. 
The main idea that falls out of this discussion is that biopharming is still in a research stage; it 
is not a developed industry with commercial products and commercial revenue. Thus, the 
valuations of products and companies are not based on market transaction for final products. 
Instead, those valuations are based on projections of the future market value to be realised 
from present research. The research presently being conducted, however, has a wide scope, as 
shown in Tables A1 and A2, appended to this report. These tables contain information on the 
compounds being researched, the organisms modified to produce the compounds, and the 
companies involved. 
 
2.2.3 Future possibilities 
The future of biopharming is generally presented as bright and revolutionary. The technology 
can be used not only for pharmaceuticals, but also for nutraceuticals and industrial 
compounds. Biopharming is said to represent the future of biologic pharmaceutical production 
because of the cost savings and ease of matching the scale of production to market demand 
for the compounds. It is also said to have the added benefits of being safer than cell culture, 
since the therapeutic proteins are produced in media less likely to be infected with viruses that 
may affect humans. 
Although the future looks bright, there are technical, regulatory, and political barriers to the 
development of the industry. The technical problems are outside the scope of an economic 
discussion; in fact, the economic and marketing literature around biopharming appears to 
assume that technical problems will be resolved with further research. Regulatory problems 
include issues of risk management and liability surrounding the genetic modified plants or 
animals; concerns for the purity of biopharmaceutical compounds and their exclusion from 
the food supply; and the standard regulatory process for the therapeutic compounds’ 
themselves. Political pressures result from the lack of consensus amongst people and 
organisations regarding genetic modification in general and biopharming specifically. 
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2.3 The economy of New Zealand 
2.3.1 Introduction 
This report now turns to a discussion of the economy of New Zealand. In assessing the 
potential impacts of introducing biopharming to the country, it is important to understand 
what the economy currently looks like. Only then is it possible to describe how it might 
change. 
New Zealand is widely recognised as having an economy with a strong foundation in biology 
and the environment. It is precisely in these areas that some of the largest impacts of 
biopharming may be felt. Economic impacts from biopharming are thus likely to affect 
predominantly the industries that rely on the country’s natural resources: agriculture and 
tourism. 
 
2.3.2 Agriculture 
The primary sector is an important contributor to the New Zealand economy, both to Gross 
Domestic Product (GDP) and to export earnings. Together, agriculture, forestry, and their 
associated sectors contributed 18 per cent of the country’s GDP in 2002/03 (Ministry of 
Agriculture and Forestry, 2005b). In addition, agricultural and silviculture exports accounted 
for over 60% of merchandise exports (Ministry of Agriculture and Forestry, 2005b). 
What follows is a brief description of several parts of the primary sector in New Zealand. It 
provides an indication of the magnitude of production based on natural biological resources 
and the relative sizes of different primary commodities. 
The dairy industry’s 12,000 milk suppliers and their 5.15 million dairy cattle produced 1.21 
million tonnes of milk solids in the 2005 season (Ministry of Agriculture and Forestry, 
2005b). About four per cent of production was used to produce fresh milk for the domestic 
market; the other 96 per cent was processed into milk powder, cheese, butter, casein, and 
other products. The dairy industry is centrally organised, with Fonterra processing 96 per cent 
of New Zealand’s milk. Over 90 per cent of milk products are exported, making the industry 
highly reliant on international markets. In addition, dairy products exports accounted for 18 
per cent New Zealand’s exports in the year to June 2006 (Statistics New Zealand, 2006b). In 
the year to March 2005, this amounted to $5.678 billion (Ministry of Agriculture and 
Forestry, 2005b). 
According to Statistics New Zealand (2006a), the national beef cattle herd was 4.4 million 
head at June 2005. Beef exports were 415,000 tonnes in 2005, at a total value of $1.918 
billion (Ministry of Agriculture and Forestry (MAF), 2005). About one-half of export beef 
goes to the US, with Asian markets as the next most important export destinations (Ministry 
of Agriculture and Forestry (MAF), 2005). 
As at June 2005, New Zealand had 39.5 million head of sheep (Ministry of Agriculture and 
Forestry (MAF), 2005). In 2004, meat production was 107,000 tonnes of mutton and 411,000 
tonnes of lamb, carcass weight equivalent (cwe). That same year, exports of mutton were 
87,900 tonnes cwe earning $255 million, while exports of lamb were 358,000 tonnes cwe or 
$1.97 billion (Ministry of Agriculture and Forestry (MAF), 2004). In 2005, lamb exports had 
a lower volume at 292,000 tonnes, but higher prices meant they were valued at $2.062 billion 
(Ministry of Agriculture and Forestry (MAF), 2005). The EU imports about one-half of the 
total volume of meat exports, paying above average prices for it. The US market is growing, 
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particularly after lifting the tariff rate quota (TRQ) in November 2001 (Ministry of 
Agriculture and Forestry (MAF), 2004). 
Eighty per cent of New Zealand wool is produced along with meat from dual-purpose 
animals; only about five per cent of the country’s wool is fine merino wool from specialty 
flocks (Ministry of Agriculture and Forestry (MAF), 2004). Production in 2005 was estimated 
to be 175,000 tonnes of wool, of which 148,000 tonnes were exported, earning $698 million 
(Ministry of Agriculture and Forestry (MAF), 2005). The largest market for New Zealand 
wool is the People’s Republic of China (PRC), with the UK and Italy also as significant 
importers (Ministry of Agriculture and Forestry (MAF), 2004). 
Commercial forestry in New Zealand is focused largely on radiata pine. Forestry exports 
accounted for ten per cent of New Zealand's merchandise exports, or a value of NZ$3,226 
million for the year to March 2004 (Ministry of Foreign Affairs and Trade, 2004)). Estimated 
roundwood removals for the year ended March 2005 were 19.3 million cubic metres (Ministry 
of Agriculture and Forestry, 2006). Removals have been decreasing by about eight per cent 
per year over the last two years because of reduced margins from lower prices and higher 
costs (Ministry of Agriculture and Forestry, 2006). Exports of all forestry products in the 
years ended June 2005 was $3.184 billion (Ministry of Agriculture and Forestry, 2005a). 
The horticulture subsector, including floriculture, accounted for over $4.8 billion dollars in 
domestic spending and export revenues in 2004/2005 of which about $2.3 billion was 
exported (HortResearch, 2005). The total area in horticulture in New Zealand is about 
110,000 hectares, spread throughout the country. Major crops by area in 2002 were wine 
grapes (17,500 ha), apples (12,500 ha), kiwifruit (12,200 ha), potatoes (10,600) and onions 
(5,680) (Burtt, 2004; Ministry of Agriculture and Forestry, 2003a). By 2005, wine grapes had 
increased to 21,002 ha, apples had fallen to 11,700 ha, kiwifruit was on 10,934 ha, and 
potatoes were on 11,289 ha (HortResearch, 2005). The major exports in 2005 were kiwifruit 
($720.2 million), wine ($432.7 million), apples ($387.0 million), and processed vegetables 
($263.7 million) (HortResearch, 2005). Floriculture exports were $39 million in 2005 
(HortResearch, 2005); the major export products were orchids, calla lilies, sandersonia, and 
proteacea (Ministry of Agriculture and Forestry, 2003a). In addition, domestic sales of cut 
flowers are estimated to be $70 million (HortResearch, 2005), bringing the total value of 
floriculture to nearly $110 million per year. The top markets for horticultural exports are the 
EU, Japan and the US, with Japan an important market for flowers, onions and squash and the 
UK an important market for wine (HortResearch, 2003). 
The arable subsector contains a number of different crops, for which statistics on production, 
prices and trends are provided in MAF (2003b). The cereal crops of barley, wheat and maize 
accounted for about 136,000 hectares in 2003/04, with barley accounting for nearly half of 
that area. Cereal production amounted to about 856,000 tonnes in that year. Small seeds, such 
as ryegrass and clover seeds, are grown on about 33,000 hectares, and field peas account for 
another 10,000 hectares of production. A small but rising part of the arable subsector is 
vegetable seed growing, which earned $25 million in 2003/04. Total exports of arable crops 
were $111 million, comprising mainly grass seed, field peas, and vegetable seeds. Estimated 
total production in arable crops was $389 million in 2003/04 (Kaye-Blake, Saunders, 
Emanuelsson, Dalziel, & Wreford, 2005). 
It is possible to disaggregate the exports from different parts of the agricultural sector using 
data from New Zealand External Trade Statistics from the Ministry of Foreign Affairs and 
Trade. Table 3 is based on statistics from 2002: 
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Table 3: Disaggregated export statistics, 2002 
Main export markets Value (million NZ$) 
Australia  5,694 
United States of America  4,793 
Japan  3,698 
United Kingdom  1,525 
Republic of Korea   1,450 
People’s Republic of China  1,419 
  
Main export products Value (million NZ$) 
Dairy  5,925 
Meat  4,423 
Wood  2,371 
Fish   1,401 
Starch, Casein  1,386 
Fruit (7th ranked)  1,156 
Vegetables (15th ranked)  447 
  
Main exports by market Value (million NZ$) 
Australia  
Dairy  300 
Meat  26 
Wood  380 
Fruit and Vegetables  215 
United States of America  
Dairy  994 
Meat  1,316 
Wood  494 
Fruit and Vegetables  154 
Japan  
Dairy  551 
Meat  253 
Wool  600 
Fruit and Vegetables  387 
United Kingdom  
Dairy  229 
Meat  540 
Wood  2 
Fruit and Vegetables  175 
Republic of Korea  
Dairy  125 
Meat  106 
Wood  450 
Fruit and Vegetables  28 
People’s Republic of China  
Dairy  207 
Meat  111 
Wood  200 
Fruit and Vegetables  21 
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 The agricultural sector, including forestry, is an important part of the New Zealand economy. 
Its contribution to the country’s exports is even larger than its contribution to GDP, making 
New Zealand relatively dependent on primary products to generate income from international 
trade. In addition to indicating the overall size of the sector, the figures here provide a sense 
of the relative importance of different products. Dairy products are the most important 
agricultural products. Beef and sheep account for around $2 billion each in exports, but 
forestry has even greater exports at over $3 billion. Horticultural products taken together 
account for a greater portion of GDP than any other part of the agricultural sector bar dairy; 
this total value is spread over a number of economically important crops. 
 
2.3.3 Tourism 
The tourism industry is an important part of the New Zealand economy. The Tourism Satellite 
Account (Statistics New Zealand, 2006c), which calculates the contribution of tourism to the 
New Zealand economy, shows a total tourism expenditure of $17.5 billion for the year ending 
March 2005, contributing nine per cent of gross domestic product. Of this amount, 54 per cent 
was contributed by domestic tourists and 46 per cent international tourists. International 
tourism expenditure accounts for 18.7 per cent of total national export earnings and is 
therefore New Zealand’s largest export earner. It is important to note that international 
tourism is the only export sector that generates GST revenue for the government with a 
contribution of 10.5 per cent ($526m) of GST receipts in 2005. Tourism is also an important 
part of the New Zealand workforce. It is estimated that tourism supports directly and 
indirectly 176,000 full-time-equivalent jobs involving 9.8 percent of the labour force 
(Ministry of Tourism, 2006b). 
Tourism is a growing sector. There was an average increase of 7.6 per cent in tourism 
expenditure between 1999 and 2003 (Tourism Research Council of New Zealand, 2004), and 
1.25 per cent between 2003 and 2005. The recent slow-down in tourism expenditure is due to 
a decrease in domestic tourism. On the other hand, international tourism has been strong. 
International visitor arrivals passed one million in 1992 and two million in 2002 and reached 
an all-time high of 2.37 million in 2005 (Ministry of Tourism, 2006b). It is forecasted that 
international visitor arrivals will reach 2.8 million in 2008 if there is no presence of 
international shocks, such as the bird flu (Scanlon, April 11, 2006). The forecasted number of 
international visitors in 2012 is 3.11 million with an expected total expenditure of $10.10 
billion (Ministry of Tourism, 2006a). 
Research confirms that tourists have a ‘clean and green’ image of New Zealand and that they 
are inclined to visit because of the unpolluted nature and beautiful landscapes (PA Consulting 
Group, 2001; Sanderson et al., 2003). A survey of international tourists in New Zealand and 
individuals in New Zealand’s main overseas tourism markets indicated that they perceive the 
New Zealand environment to be above average and among the best in the world (Sanderson et 
al., 2003). Research conducted by TNZ and Colmar Brunton (New Zealand Tourism Board, 
1995, 1997) also shows that it is the tourists’ perception of the clean and green environment 
in New Zealand that motivates them to visit. Tourists are attracted to the beautiful scenery and 
landscapes, and the opportunity to engage in nature-focused experiences (PA Consulting 
Group, 2001). This suggests that New Zealand tourism is largely dependent on the ‘clean and 
green image’ and this image needs to be maintained to remain competitive in the global 
tourism market. For this reason, threats to the New Zealand environment may have a negative 
impact on tourism and the New Zealand economy. 
A report published by the Ministry for the Environment (PA Consulting Group, 2001) 
estimated the export value of New Zealand’s ‘clean and green image’, and surveyed the 
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change in tourists purchasing behaviours under worsened environmental conditions. Tourists 
from New Zealand’s top five tourist markets (Australia, USA, UK, Japan and Korea) were 
provided with two sets of images. One set depicted the current state of the New Zealand 
environment with images typically used to promote New Zealand as a tourist destination 
overseas, and the second set depicted images of New Zealand with a degraded environment. 
The respondents had to indicate if the two different sets of images would have made them 
stay a different number of days in New Zealand, and if so, how many days they would have 
stayed under the different conditions. The results showed that the tourists were likely to spend 
less time in New Zealand under the degraded environmental condition and the estimated 
annual tourism expenditure loss was $530 million (based on figures for the year ending 2001). 
This figure includes the loss of direct tourism expenditure and GST revenue. It is important to 
note that the loss figure only represents tourism expenditure from the top five tourist markets 
and the figure would be greater if all other tourist markets were included. The result from this 
study confirms that worsening environmental conditions negatively affect tourism 
expenditure. 
The clean environment not only benefits international visitors, but also New Zealand residents 
(Hughey, Kerr, & Cullen, 2004). The high level of environmental quality in New Zealand can 
be attributed to the low population density resulting in modest environmental pressures (PA 
Consulting Group, 2001). However, there are some aspects of the New Zealand environment 
that are under pressure, such as rivers and lakes, marine fisheries and air quality (Hughey et 
al., 2004; PA Consulting Group, 2001). Hughey et al. (2004) found that New Zealanders 
believe that water pollution is the most important environmental issue and many of them are 
willing to pay a $20 per year increase in rates to fund lowland stream enhancements. The 
value of park visits has been assessed in three main cities. The value per park visit for the 
Auckland Regional Council was estimated to be $11.50 per person (Saunders, Cullen, & Ball, 
1999). Another study found a similar figure for Wellington parks (Kerr, 1996). A 
Christchurch study for a single park found a much lower per-visit value, at only $1.60 per 
person (Walker, 1992). This research suggests that the clean and green environment is also of 
value for domestic tourists. 
 
2.3.4 New Zealand economy: conclusion 
New Zealand’s economy has a significant portion that is based on natural resources. The 
agricultural sector depends on the biological resources to produce not only food and fibre for 
the domestic population but also for a large percentage of the country’s exports. International 
tourism also depends on the country’s natural resources, its biology and landscape, and adds 
significantly to the country’s export earnings. Tourism exploits New Zealand’s image as a 
clean and green destination. 
Biopharming also depends on natural resources, and is thus a potentially competing claim on 
these resources. Whether the net impact on the New Zealand economy is positive, negative, or 
neutral depends on the ability of these different industries to use the resources productively. It 
also depends on potential spill-over effects – externalities in the language of economists – and 
how large those effects are. 
 
2.4 Economic analyses for New Zealand 
While biopharming promises to revolutionise production of pharmaceuticals, there are 
elements of the industry that suggest comparisons with other areas of research. In particular, 
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the production of pharmaceutical compounds using biopharming relies on genetic 
modification to engineer the production of the novel compounds; the plants and animals used 
in biopharming are genetically modified organisms (GMOs). Thus, to understand the potential 
impact of introducing biopharming, one can examine the literature on the potential impact of 
GMOs in New Zealand. 
 
2.4.1 Macroeconomic analyses 
The Independent Biotechnology Advisory Council (IBAC) prepared an early economic 
analysis of the impact of GMOs, Economic Implications of a First Release of Genetically 
Modified Organisms in New Zealand (Campbell et al., 2003; IBAC, 2000). Jan Wright (a 
member of IBAC) relied on these findings for her submission to the Royal Commission on 
Genetic Modification (RCGM). The IBAC paper and Wright’s submission indicated that there 
were serious economic issues with GM in agriculture, particularly with the ‘first release’. 
Wright suggested that the RCGM look closely at economic issues (Campbell et al., 2003; 
Wright, 2000). 
In the event, the RCGM did not fully explore the economics of GMOs, and in particular did 
not receive independent advice regarding the economics. A number of submissions came from 
entities with economic interests in GM, either for or against (Nana, 2000; Stroombergen, 
2000; Wright, 2000), but the economic research was remarkably thin (Campbell et al., 2003).  
One example of economic research presented to the RCGM was Infometrics’ analysis in 
support of the Life Sciences Network. Infometrics used a Computable General Equilibrium 
(CGE) model to simulate the effects of several scenarios regarding using or restricting the use 
of GM in New Zealand (Stroombergen, 2000). While the findings were generally positive for 
GM crops, the results were unsurprising given the assumptions driving them. Nana (2000) 
reviewed this RCGM submission and noted that modelling the robustness of the effects or the 
impacts of closely related scenarios would have provided more useful results. Furthermore, 
Nana found that the actual model used probably overstated any impacts of GM crops on the 
NZ economy. Thus, Nana did not find that the result provided clear, unqualified empirical 
support for pursuing GM. 
 
An important lesson from the Infometrics modelling was the importance of accurate and 
transparent assumptions for modelling. Campbell, et al. (2003) also suggested that comparing 
a future possible industry-wide practice with a minority sector like organic agriculture was 
problematic. 
A second economic analysis presented to the Royal Commission was based on the Lincoln 
Trade and Environment Model (LTEM) (Saunders & Cagatay, 2001). The LTEM was 
initially used to simulate various scenarios relating to adoption of GM crops in NZ, including 
reduced costs of production, premiums for and against GM and bans for GM products in key 
markets Japan and the EU (Saunders & Cagatay, 2001, 2003). The results of the scenarios in 
which New Zealand adopted GM crops were generally negative for NZ, even when a 
preference for GM products and/or increased productivity was modelled. Saunders & Cagatay 
(2001) outlined their findings as being generally negative for the adoption of GM in primary 
production sectors. Further modelling work has in general supported these conclusions 
(Saunders, Kaye-Blake, & Cagatay, 2003). This later work found that for GM to have positive 
impact on producer returns NZ must be able to retain productivity benefits for itself and/or the 
GM product must have a premium. 
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Another source of economic analysis of GM crops in NZ is a report that the Ministry for the 
Environment (MfE) commissioned from Business and Economic Research Limited (BERL) 
and the AERU (Sanderson et al., 2003). As part of that research, surveys were conducted in 
several key overseas markets. These surveys found that New Zealand’s image as an 
environmentally friendly country would be hurt by the release of GM organisms, and demand 
for NZ products would suffer. The report found that consumers’ reactions were an important 
influence on New Zealand’s international trade, but that productivity increases or cost savings 
on the farm were much less important. The overall effect on GDP from commercial use of 
GMOs in agriculture could be either negative or positive, depending on how consumer 
reactions affect actual trade and how GM technology affects actual production. 
Research conducted to inform the economic modelling for the MfE report provided new 
information on how overseas consumer might react to the introduction of a GMO into the 
New Zealand environment. The survey research found that 27 per cent of Australians, 20 per 
cent of US citizens, and 30 per cent of Britons were opposed to the use of GMOs. These 
figures are on a par with the results of other research discussed below. In addition, the NRB 
research found that nine per cent of Australians, five per cent of US citizens, and six per cent 
of Britons would stop visiting New Zealand if a GMO were released in the country. 
Further research has explored the dynamic interaction of consumer willingness to pay for 
premium products and the impacts of productivity on farmers’ returns. Using results from a 
nationwide survey of New Zealanders’ preferences regarding a variety of biotech products, 
Kaye-Blake, Saunders and Fairweather (2004) estimated the maximum gains that were 
possible from producing crops which commanded a premium. They found that growers of the 
most favoured GM product, anti-oxidant apples, would be able to charge a 17 per cent 
premium to 26 per cent of the apple market, leading to an average increase in industry 
revenues of 4.3 per cent. Anti-oxidant apples are an example of a functional food, so these 
findings are relevant for biopharming broadly defined. 
There have also been some modelling activities in the Australian context that are relevant to 
the New Zealand economy. A Productivity Commission Report (Stone, Matysek, & Dolling, 
2002) applied the global general equilibrium modelling framework GTAP (Global Trade 
Analysis Project) to examine potential impacts of GM technology on Australia’s trade in non-
wheat grains and oilseeds. The results of the three scenarios considered demonstrated that 
very small ‘absolute changes’ would occur in Australia’s import and export flows. Rather, 
regions with currently significant GM sectors (such as North America) felt the most 
substantial impacts to trade and income. Two assumptions are critical to their findings: 
incompletely-adopting countries (Australia, New Zealand, and the EU) have an added 
regulatory burden that increases supply costs, whereas North America does not; and 
consumers who do not want GM crops do not have increased welfare from having access to 
sources of non-GM food. The authors conclude from their findings that a longer-term 
expansion of GM technology could have significant negative impacts on Australia’s and New 
Zealand’s trade position. 
 
2.4.2 Consumer research 
Finally, attitudes and perceptions of New Zealanders have been studied by social scientists at 
two Crown Research Institutes. One report compares the results of two telephone surveys 
(Gamble & Gunson, 2002). Generally, women are less sanguine about GM food than men, 
and are more likely to have changed their food purchasing behaviour due to concerns about 
GM. In addition, a product that is itself modified is less acceptable than a non-modified 
product produced using GM (such as beef fed with GM clover). 
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Another report (Small, Wilson, & Parminter, 2002) analyses the results of a postal survey. 
These results show somewhat less support in New Zealand than the above research. However, 
a majority of respondents were willing to support GM food in some circumstances. On the 
other hand, GM did not fit with respondents’ personal beliefs. 
Peer-reviewed research has also examined consumer reactions to genetically modified food. 
Kassardjian, Gamble, & Gunson (2005) used experimental auctions to determine the 
willingness of participants to exchange non-GM apples for GM apples with defined benefits. 
They found that 28 per cent of participants were not interested in the GM apples, while the 
majority was willing to pay between NZ$0 and NZ$0.50 extra for apples providing either 
environmental or health benefits. No difference in prices was found between the two types of 
products. They also found that participants felt a need to interact with the products, and that 
engagement in biotechnology positively affected willingness to pay. Kaye-Blake, Bicknell, & 
Saunders (2005) employed a choice modelling survey, which also collected information on 
willingness to pay for GM apples. They also found that a significant minority of consumers 
were not interested in GM apples. For some who were willing to buy GM apples, the price 
reductions were quite large, while for other respondents the price reductions were not 
statistically significant from zero. Thus, both of these articles suggest that a majority of 
consumers are willing to buy GM food, but that the prices demanded by these consumers have 
a considerable range. 
 
2.5 Analyses of impacts on other countries 
Further information about the potential impacts of introducing GMOs into New Zealand for 
the purposes of biopharming can be derived from overseas research. This research is 
particularly valuable as GMOs are currently commercially grown in some other countries, 
whereas they are not intentionally grown in New Zealand. From an economic perspective, it is 
helpful to divide impacts into those that affect production or supply and those that affect 
consumption or demand. These two sides of the market are then analysed together in the 
macroeconomic and trade literature. Production, consumption, and trade are thus handled in 
turn in the discussion below. 
 
2.5.1 Production impacts 
Much of the research on production impacts of biotechnology has focused on simple 
productivity gains. That is, they estimate the impacts of biotechnology from enabling farmers 
to produce commodity crops more efficiently (e.g., Frisvold, Sullivan, & Raneses, 2003). The 
impacts of biotechnology to date, especially in New Zealand, have been largely on 
productivity (Kaye-Blake, Saunders et al., 2005), so there is some merit to this focus. 
However, biopharming produces a different kind of product. Rather than producing 
agricultural commodities in greater amounts, it produces a pharmaceutical product in a novel 
way. Analyses of productivity impacts are therefore of limited use. The literature on second-
generation GM crops, which are products with enhanced attributes, such as nutraceuticals or 
functional foods, provides some guidance, however. The allure of these products is the 
increased profit from a price premium that consumers would pay. These would be value-
added products that move producers out of the commodity market and into a market with 
higher profit margins. However, these products are also likely to lead to changes to the 
structure of agricultural sector, both through concentration of the control of inputs and desire 
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for quality control over these enhanced products (Caswell, Fuglie, & Klotz, 1998; Oehmke & 
Wolf, 2002). 
Furthermore, the experience of an already-released functional food crop, the Flavr Savr 
tomato, shows that making a profit from enhanced products is not a foregone conclusion. As 
detailed in First Fruit: The Creation of the Flavr Savr™ Tomato and the Birth of Genetically-
Engineered Food, (Martineau, 2001), genetically engineering a tomato to delay rotting was 
only part of the genetic work in producing a better-tasting, premium tomato. A significant 
problem was that commercial tomato varieties have been bred for toughness rather than taste, 
so they produce mediocre tomatoes whether rotting is delayed or not. A further problem had 
nothing to do with genetics and everything to do with business: Calgene, the company that 
developed the tomato, did not understand the fresh-market tomato business or its own product 
sufficiently to be successful. The GM tomato was pulled from the market after only a few 
years. 
One peer-reviewed analysis of the economics of biopharming has been published (Kostandini, 
Mills, & Norton, 2006). It focused on the production of human serum albumin (HSA) in 
tobacco as a case study for biopharming. The market for HSA was modelled with linear 
supply and demand functions, and the results of a price reduction on the market were 
estimated both when the producer had monopoly power due to its innovation and when it did 
not. In the first case, the innovation resulted in excess (monopoly) profits for the firm. It did 
not benefit consumers, however. In addition, tobacco farmers were either unaffected or left 
worse off; they provided the tobacco at cost as a result of the relative market power of the 
farmers and the innovating firm. The latter case, without the monopoly, is assessed as 
unrealistic: the firm would not pursue the innovation unless it could secure monopoly pricing 
power. This modelling suggests that control of the innovation is important, and that 
widespread welfare gains from biopharming may be unlikely. 
 
2.5.2 Consumption impacts 
The impacts of biopharming on consumption can be considered at two levels. The first level is 
the consumption of the pharmaceutical compounds themselves: the market for the 
compounds, the maturity of the market, and the competitiveness of the market. These issues 
have received essentially no consideration in the academic economic literature, and it is thus 
difficult to reach any firm conclusions. However, given the information presented above 
regarding the types of compounds that are being produced with biopharming – well-
understood compounds that may be manufactured in a number of ways – it would seem that 
the market for these compounds is relatively mature and stable. The size of the market for any 
individual compound could be assessed through industry sources, and competition is likely to 
be on the basis of cost. 
The second level to consider for the consumption side of the market is the overall impact of 
releasing novel GMOs with biopharmaceutical properties. The consumer impacts of releasing 
GMOs has been studies extensively, so there is a body of literature from which to draw. 
An important finding from this research is that all biotechnology applications do not provoke 
similar responses. Broadly speaking, medical uses of biotechnology are more acceptable than 
food uses, and biotechnology focused on plants is more acceptable than animal biotechnology 
or plant-animal genetic transfers. The same hierarchy of acceptance is evident in Australia, 
New Zealand, North America, and Europe (Campbell et al., 2003). The ramification of this 
hierarchy when medical compounds are produced in food plants is, however, unclear. 
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Another aspect of differential responses to biotechnology application is the variability 
amongst countries. Several researchers have found that North Americans are more accepting 
of biotechnology in general than are Europeans (Campbell et al., 2003; Hoban, 1997). 
The impact of knowledge on attitudes towards biotechnology is a more difficult question. One 
early review of opinion polls found that people who learned more about GM became more 
accepting of it (Zechendorf, 1994). However, this finding does not always hold, and has been 
specifically countered in recent research in the UK, where people’s attitudes hardened as they 
learned more about GM (Heller, 2003). 
Risk perceptions regarding biotechnology are an important topic of research. Generally, lower 
acceptance of biotechnology is tied to greater risk perceptions. One specific concern that has 
been raised is concern for the unintended consequences of the technology (Norton, 1998 in 
Campbell et al., 2003; Heller, 2003). There is some question about how risks and benefits of 
the technology are perceived and assessed. Fischhoff & Fischhoff (2001) and Gaskell et al. 
(2004) have suggested that risks and benefits are not combined into a unidimensional scoring 
of the value of the technology, but that they act as thresholds in individuals’ decision-making 
processes. 
The PABE project (Marris, Wynne, Simmons, & Weldon, 2001) used in-depth research to 
examine these attitudes in more detail than is possible with opinion polls. Two important 
overall findings that challenged conventional wisdom in the area of consumer attitudes to GM 
were that attitudes did not vary much in the five countries studied, and that people were not 
simply ‘for’ or ‘against’ GM per se. The report focused on dispelling myths that have built up 
around consumer perceptions, suggesting that these myths have creating a gulf of 
understanding between consumers on the one hand and government and industry on the other. 
The emphasis of this report is on the understandings and knowledge that consumers use to 
make decisions about biotechnology, and in particular about GM food. Although the general 
public may not have the specialist knowledge of a geneticist, they are not basing their 
decisions on that type of knowledge. Instead, they use their empirical knowledge of past 
institutional behaviour, especially of lapses in public safety. ‘Signal’ events (Flynn, Slovic, & 
Kunreuther, 2001) such as the BSE crisis are perceived to be examples of the normal 
behaviour of institutions charged with protecting the public safety. 
Individuals have often expressed ambivalence about GM technology (Marris et al., 2001). 
They seem to recognise that there were both positives and negatives, and many factors came 
into play when they made decisions regarding specific biotechnology applications. 
Ambivalence is also how the UK public was described in a report synthesising results from 
the Eurobarometer surveys from 1996 to 2002 and additional surveys (Gaskell et al., 2003). 
The Eurobarometer polls are generally useful for assessing European attitudes towards 
biotechnology. Britons were found to be getting less negative towards GM in general between 
the 1999 and 2002 surveys, and significant percentages claimed to be keeping an open mind 
on the issue. In addition, it was clear that Britons also make clear distinctions between 
different types of biotechnology. The majority do not support GM food, while GM medical 
applications are generally acceptable. 
The results of research into overseas consumers’ attitudes towards biotechnology raise some 
important issues. First, given the apparent hierarchy of approval, with medical biotechnology 
more supported that food biotechnology, the reaction to producing medical compounds in 
food is potentially ambiguous. Secondly, consumer reactions are not unidimensional, but are 
complex and can be influenced in unpredictable ways. Factors like risk perceptions and 
knowledge of the technology do not have simple, unambiguous impacts on consumer 
reactions. 
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The literature on public and consumer perceptions of biotech food and the economic research 
described above suggest that the decision of what food to purchase is complex and affected by 
consumer awareness, environmental concerns, labelling, and product experience, in addition 
to the use of genetic technology. Ceteris paribus, non-GM food is preferred over GM food. 
However, if pharmaceutical or nutraceutical properties can be made available to consumers 
through genetic modification, some consumers may be willing to pay a premium for these 
products. Certainly, research in New Zealand suggests that there is a consumer segment that is 
comfortable with biotechnology and interested in improved food products (Kaye-Blake, 
O'Connell, & Lamb, 2007). 
There are two broad conclusions that can be drawn from this review of consumer studies. The 
first is that there is a great degree of variability with regard to responses to and demand for 
biotech food crops. Levels of consumer concern vary by country and vary strongly by actual 
application of biotechnology. The second conclusion is that there is likely to be some 
resistance to biotech food as a potential export product from New Zealand. In every country 
studied, non-GM foods are preferred to GM foods. Furthermore, there is a market segment 
that finds GM foods unacceptable, regardless of other product attributes. Since around 1995-
1996 this segment of the market in many Western countries has developed negative attitudes 
towards GM food. Levels of trust and perceptions of risk associated with biotechnologies are 
increasingly related to broader concerns about ethics, food morality, regulation and food 
safety, and the perceived politics of food trading. This resistance in key markets has become 
relatively stable and comprises a minority segment of some of New Zealand’s key markets. 
 
2.5.3 Environmental values 
The previous sections reported on research conducted by social scientists that tended to focus 
on the distinction between food and medical uses of biotechnology. An important third area of 
interest in New Zealand is the potential for biopharming technologies to have environmental 
benefits. 
Environmental values are an important part of perceptions of GM food (Bredahl, Grunert, & 
Frewer, 1998; Cook, 2000). However, the relationship is not straightforward. Researchers 
found that favourable attitudes towards nature correlated with negative attitudes towards GM 
(Bredahl, 2001). More specifically, survey respondents did not agree that GM is 
environmentally friendly (Small et al., 2002), and ecocentric respondents (those that value 
nature intrinsically) did not support GM (Siegrist, 1998). Likewise, those who felt that the 
costs of technological growth and energy consumption were too high tended to have negative 
attitudes towards GM (Sparks, Shepherd, & Frewer, 1994). In general, acceptance of GM was 
less likely when there is greater environmental risk (Macer, 1992; Small et al., 2002). In fact, 
the Organisation for Economic Cooperation and Development (OECD) has attributed the lack 
of acceptance of rBGH outside the US to concern for animal welfare (Organisation for 
Economic Co-operation and Development, 2000). 
Some surveys that attribute environmental benefits to biotechnology in agriculture find 
positive reactions. In the IFSC/Wirthlin Group/Cogent Research surveys, respondents were 
asked whether they would buy biotechnologically derived food that required fewer pesticide 
applications and whether they would buy biotechnologically derived food engineered to taste 
better or stay fresher. Consistently, respondents express more support for the biotechnology 
application that has an environmental benefit (IFIC, 2002) than for applications that do not. 
Canadian, New Zealand, and Australian research has revealed a similar pattern (Macer, 1994; 
Sheehy, Legault, & Ireland, 1998). 
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What is apparent is that genetic modification of food and environmentally-friendly farming 
pull consumers in opposite directions. Choice modelling research in Western Australia found 
that respondents would purchase GM food at a 20 per cent to 47 per cent discount, but would 
also pay 36 per cent more to reduce agrochemical use by 30 per cent (James & Burton, 2001). 
The format of choice modelling surveys generally highlights tradeoffs that respondents could 
make, but this particular study was not designed in such a way to estimate the willingness to 
pay for GM food crops that used markedly fewer pesticides. 
The combined effect of using genetic technology to achieve environmental goals was 
examined in research for the NZ Ministry for the Environment (Sanderson et al., 2003). 
Respondents from Australia, the U.K., and the U.S. were surveyed on how their image of 
New Zealand would change were the country to use genetic technology to control a pest 
population. Overall, 25 per cent said their image would improve, 29 per cent said it would 
remain the same, and 32 per cent said it would get worse. By contrast, if New Zealand were to 
be one of a few countries not to release GM organisms into the environment, 33 per cent said 
their image would improve, 59 per cent said it would remain the same, and six per cent said it 
would worsen. These results suggest that some people are comfortable with the use of genetic 
technology to achieve environmental goals, whilst others are not. 
Environmental values seem to cut both ways. To the extent that biotechnology may represent 
a perceived threat to the environment, some consumers may see it as a negative development. 
To the extent that biotechnologies are perceived to reduce environmental damage, they may 
become more valuable. 
 
2.5.4 Estimated trade impacts 
The trade impact of introducing GM has been estimated by several studies. Moschini, et al. 
(2000) attempted to quantify the effects on production, price and welfare of adoption of 
roundup ready (RR) soybeans. This study used a three-region, US, South America and the 
Rest of the World (ROW), bilateral partial equilibrium trade model and they focused only on 
soybean and soybean products (meal and oil). To model the innovation at the production 
level, Moschini, et al. (2000) first quantified the per hectare cost, profit and yield effects of 
RR soybean seed adoption. They then calculated the price effects of quantitied changes in the 
innovator country. The effect of trade polices in their model were assumed to be captured by 
price differentials between the regions. Finally, Moschini, et al. (2000) quantify the consumer 
and producer surplus measures of welfare effects of RR adoption in the innovator country and 
in the other regions. They also provided the welfare effects under the assumption of 
international technology spill-over from innovator country to other regions. They found that 
U.S. farmers are better off in the base scenario. However, they were worse off if the 
technology increased their yields, and they do not gain nearly as much if other countries also 
adopt the technology. 
Nielsen, et al. (2000) analysed the impact of consumers' changing attitude toward genetically 
modified organisms (GMOs) on world trade patterns, with emphasis on the developing 
countries. They used a multi-regional computable general equilibrium (CGE) framework that 
modelled the bilateral trade among seven regions: High-Income Austral-Asia, Low-Income 
Asia, North America, South America, Western Europe, Sub-Saharan Africa and the ROW. 
Production was aggregated into ten sectors in each region, including five primary agricultural 
products (cereal grains, oilseeds, wheat, other crops, and livestock), three food processing 
industries and a manufacturing and services industry at aggregate level. The goods are 
assumed to be imperfect substitutes in the international market.  
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Nielsen, et al. (2000) included the GM and non-GM production of maize and soybeans sectors 
in their model. Initially, they assumed an identical production structure in terms of the 
composition of intermediate input and factor use in the GM and non-GM varieties and also 
the same structure of exports in terms of destinations for both varieties. The producers’ and 
consumers' decision to use GM versus non-GM varieties in their production and final demand 
respectively was endogenised for maize and soybeans sector. For the other crops, intermediate 
demand was held fixed as proportions of output and final consumption of each composite 
good was also fixed as a share of total demand. 
The policy scenarios were based on the assumption that the GM-adopting sectors did make a 
more productive use of the primary factors of production as compared with the non-GM 
sectors. Therefore, they introduced a ten per cent higher level of factor productivity in GM-
adopting maize and soybean sectors in all regions as compared with their non-GM 
counterparts. The factor productivity shocks were introduced in alternative scenarios which 
differ in terms of the degree to which consumers and producers in high-income regions found 
GM and non-GM products substitutable. Starting from the perfect substitution case they 
lowered the degree of substitution among GM and non-GM maize and soybeans in production 
and consumption as the citizens of high-income, Western Europe and High-Income Austral-
Asia, regions became more sceptical of the new GM varieties. In the other regions, the 
citizens were assumed to be indifferent, and hence the two crops remained highly 
substitutable in those production systems. 
Nielsen, et al. (2000) included NZ in High Income Asia group. They found that trade 
diversion became significant when the GM-critical regions changed their preferences towards 
Non-GM products. The trade of GM-varieties was found to divert towards GM-indifferent 
markets and Non-GM varieties diverted towards GM-critical regions. This was explained as a 
result of the price differential between GM and Non-GM varieties, which was a consequence 
of factor productivity differences in the production of these varieties. However, the degree of 
the price differential and its impact on supply showed differences between the GM-critical 
and GM-favourable regions. In particular, in GM-favourable regions the prices of the Non-
GM varieties declined as well as the price of GM-varieties, due to the high degree of 
substitution between the two varieties in consumption and to the increased production to 
supply to GM-critical regions. In the GM-critical regions on the other hand, the price 
differential impact on the supply of Non-GM goods was minor. Moreover, as there was not 
perfect substitutability between GM and Non-GM products in these regions, there was still the 
possibility for both varieties to access the GM-critical markets. 
In a similar work that focuses on production of GM maize and soybean crops, Anderson & 
Nielsen (2000a) use a CGE model, GTAP (Global Trade Analysis Project), to quantify the 
effects on production, prices, trade patterns and welfare of certain countries adopting GM 
maize and soybean crops. They analyse the policy impacts in various scenarios with and 
without considering the trade policy and/or consumer reactions to GMOs. GTAP is a static 
CGE model that provides the bilateral trade relations among countries by using the 
Armington (1969) approach to differentiate the products. Anderson & Nielsen focus on 17 
industries of which agricultural production is disaggregated into coarse grains, oilseeds, 
livestock, meat and dairy products, vegetable oils and fats, and other foods. The world is 
aggregated into 16 regions in which North America, Southern Cone, China, India, Western 
Europe, Sub-Saharan Africa, Other High-Incomes and Other Developing and Transition 
Economies are specified explicitly. 
The policy scenarios are based on the assumption that the GM-adopting sectors experience a 
one-off increase in total factor productivity (including all primary factors and intermediate 
inputs) of 5 per cent  thus lowering the supply price of the GM crop to that extent. Anderson 
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& Nielsen first analyse the impacts GM-driven productivity growth of 5 per cent in the related 
countries when others such as Western Europe, Japan, Other Sub-Saharan Africa are assumed 
to refrain from using or be unable to adopt GM crops in their production systems. In another 
scenario, the case of a policy and/or consumer response in Western Europe is introduced by 
banning the imports of maize and soybean products from GM-adopting regions. This scenario 
is based on the implicit assumption that labelling enables Western European importers to 
identify such shipments. The distinction between GM-inclusive and Non-GM products is 
based directly on the country of origin, and labelling costs are ignored. In a subsequent 
scenario, consumers in Western Europe are assumed to shift their preferences away from 
imported coarse grain and oilseeds and in favour of domestically produced crops. This 
scenario involves an exogenous 25 per cent reduction in final consumer and intermediate 
demand for all imported maize and soybeans. Incomplete information about the imported 
products in terms of whether they are non-GM or not is the implicit assumption behind this 
scenario. 
Anderson & Nielsen (2000a) include NZ implicitly in Other High Income countries. They 
analyse the impact of policy scenarios on Other High Income economies by showing the 
change in economic welfare. In the case of GM adoption by other regions (except Western 
Europe), their findings show that the increase in economic welfare (equivalent variation) of 
Other High Income group is higher when Western Europe bans the GM imports, compared to 
‘no policy response’ case. The same result also applies when consumer preferences in 
Western Europe shift towards non-GM varieties and away from GM products. The same 
results are reported in Anderson & Nielsen (2000b). 
In addition, Anderson & Nielsen note that the analyses do not account for any increase in 
welfare Europe might derive from having access to non-GM products. A major weakness of 
measuring impacts of GM technology in terms of welfare changes is: if the demand for Non- 
GM food is not explicitly modelled, then the analysis of welfare gains or losses is incomplete. 
Furthermore, Anderson & Nielsen note that ‘the cost of banning GMO imports in Western 
Europe amounts to barely US$15 per capita per year – hardly a major impediment to 
imposing an import ban’ (p. 14). Given such a low cost and the high willingness to pay for 
non-GM food, the likelihood that Europeans gain consumer welfare from a ban on GM food 
is quite high. 
Jackson & Anderson (2003) use a similar GTAP model to estimate intra-national distributive 
impacts. They model several scenarios, including: increases in productivity enhancements 
alone and productivity increases with different regulatory and labelling policies. They find 
that aggregate welfare in North America increases in all model scenarios, but that Australasia 
gains when other countries ban GM products and lose welfare otherwise. Importantly, they 
show that European agricultural producers gain from a ban on GM imports, suggesting that 
pressure for a GM ban or GM labelling is not solely consumer-driven. 
Another example of GTAP modelling is the report by the Productivity Commission in 
Australia (Stone et al., 2002) discussed above with the New Zealand research. The overall 
conclusion is that adoption of GM crops will not have a large impact on Australia’s trade. The 
report does however suggest that Australia could lose market share in the long term and 
therefore export earnings if it does not expand its GM sector. 
This message, that Australia and New Zealand could lose market share and income if they 
forego GM crops, is echoed in a report from the Australian Bureau of Agricultural and 
Resource Economics (ABARE) (Abdalla, Berry, Connell, Tran, & Buetre, 2003). Although 
the focus of the report is developing countries, it also reports that Australia and New Zealand 
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are unlikely to benefit from GM crops. The report advocates adopting GM crops, however, in 
order to limit losses in the event of worldwide adoption. 
This above report demonstrates the difficulties inherent in relying on overseas research to 
assess impacts on New Zealand. Results are reported for Australia-New Zealand as a whole. 
Terms of trade for the region decline from large-scale adoption of cost-saving GM 
technology, but the region gains from reduced agricultural imports due to increased domestic 
production and cost savings in related industries, such as livestock production. However, New 
Zealand is likely to see less benefit than Australia from these impacts. Increased consumption 
of domestic production will be lower in New Zealand because of the products modelled. In 
addition, New Zealand’s lower reliance on grain and oilseeds in its livestock production will 
see it gain relatively less than other countries. Thus, research that analyses New Zealand’s 
specific situation is more helpful than more aggregated research. 
Critically, Abdalla, et al. (2003) make no allowance for consumer attitudes. GM and non-GM 
products are assumed to trade at the same international price. The modelling therefore 
simulates the effect of a cost-saving technology that does not produce a differentiable product 
and whose adoption is geographically uneven. Consumers are not better off for being able to 
purchase products they prefer, and producers are unable to capture any premium from 
reaching those consumers. In essence, Abdalla, et al. (2003) present half a model. They 
consider the production impacts, but ignore the consumer impacts. 
 
2.5.5 Actual impacts 
Adoption of biotech commodities can affect the amount of goods traded and/or the price 
received. There has been only a little research on the trade price impact from adoption of 
biotech crops. The Tokyo Grain Exchange, for example, provides trading in futures contracts 
for non-GM soybeans. The premium over a standard contract is approximately the same as 
segregation costs (Parcell, 2001), suggesting that whilst there is a premium there are no 
excess profits for non-GM soybeans. Similar premiums are reported in Europe, with the 
USDA reporting premiums under US$4.00 per ton to cover the costs of testing (USDA, 
2001). In both Japan and the EU, it is suggested that there is sufficient supply of non-GM 
soybeans so that large premiums are not required (Parcell, 2001; USDA, 2001). 
The impact on trade volumes is more difficult to assess, and evidence is largely anecdotal. A 
summary of the impacts is available in the ABARE report, ‘Market access issues for GM 
products’ (Foster, Berry, & Hogan, 2003): Canada lost the EU as a market for canola, the US 
lost most of its maize exports to the EU, and Brazil has gained ground in the world soybean 
market, possibly as a result of its non-GM soybeans. One common assertion is that the US has 
lost around US$300 million per year in maize exports to the EU (INL Newspapers, 2003). 
Another impact is that the EU has shifted its in-quota supplier of maize, seemingly in reaction 
to the expansion of GM production in exporting countries (Agra Europe, 2000). Other similar 
anecdotes appear in the popular and trade press. However, no systematic study seems to have 
been made except the ABARE report, and that report is itself based on limited evidence. 
The overall impression from the trade press is that international trade is fulfilling its basic 
function: it is getting the right products to the right markets at competitive prices. Non-GM 
commodities are going to GM-sensitive uses in GM-sensitive markets, whilst GM 
commodities (and co-mingled commodities) are going to GM-indifferent uses and markets. 
Inhibiting analysis in this area is the fact that data sources do not distinguish between GM and 
non-GM commodities. Comparisons of GM-indifferent and GM-sensitive markets are also 
difficult due to data reasons. A further question is the cross-commodity impact of the 
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commercial release of biotech products. Again, this topic has received scant attention. The 
ABARE report mentioned above does discuss the issue, if only to say that no cross-
commodity impacts have been seen. Because of this lack of research, this report cannot 
provide any information on actual cross-commodity impacts of adoption of GM crops. 
The actual impact that crops produced by biotechnology have had on international trade is an 
important topic, and it appears that there is scope for internationally important research in this 
area. 
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Chapter 3 
Theory of Impacts 
 
 
3.1 Introduction 
The economic theory relevant to biopharming is extensive. It touches on supply and 
production, imperfect competition, demand and consumption, externalities, and risk. These 
topics form the basis of the following discussion.  
 
3.2 Supply/production 
There is currently nearly no commercial biopharming, in the sense of biopharmaceutical 
products being produced in agricultural systems for retail sale to final consumers. There is, 
however, much discussion of the potential. The question arises, then, of how to get from here 
to there, of what will happen when the industry moves from a situation of 84 
biopharmaceuticals (Elbehri, 2005) on the market being produced in contained cell culture at 
a price of about $1000 per gram to a situation in which therapeutic proteins are produced 
through biopharming at a cost of, for example, $50 per gram. 
It is possible to represent this change with a model. In this model, the cost of producing a 
compound is directly related to the characteristics of that compound; each compound may be 
viewed as a bundle of characteristics. If each characteristic is viewed as discrete, then it is 
possible to assign a cost to each one. The total cost of each compound is thus a function of the 
costs of the characteristics and the amount or level of the characteristics in each compound. 
For example, a biologic compound can be considered as a vector of characteristics (Fischer & 
Emans, 2000; Goldstein & Thomas, 2004; Kermode, 2006; Ma et al., 2003; Stoger et al., 
2002): 
[Cost/storage, Distribution, Gene size, Glycosylation, Multimeric protein 
assembly, Production cost, Production scale, Production vehicle, Propagation, 
Protein folding accuracy, Protein homogeneity, Protein yield, Public perception of 
risk, Safety, Scale-up costs, Therapeutic risk, Time required, Uncertainty].  
A biologic compound could be produced using mammalian cell culture, which is current 
technology, or can be produced using biopharming. Using cell culture, the cost of the 
compound could be:  
 
Ccc = βn*kcc = 1000 dollars per gram,  
 
where C is the cost, cc denote cell culture technology, β represents the costs of the 
characteristics, n is the number of characteristics, and k denotes the characteristics identified 
above. The sum of the characteristics multiplied by their costs is equal to the total cost of 
production. Using biopharming, the cost is estimated to be: 
 
Cb = βn*kb = 50 dollars per gram,  
 
26  
where b denotes biopharming and all other terms are as defined above. The values for the βs 
are constant across the technologies, weighted for each compound by the associated level of 
k. In principle, if the levels are known and given the prices of different compounds produced 
in different ways, it would be possible to estimate βs. However, they are largely notional, 
used to create a model for approaching the economics of the issue. 
The economics can be shown as follows. The adoption of biopharming entails a movement 
from cell culture to biopharming. The cost shifts from $1000 per gram to $50 per gram. There 
are also associated changes in the levels of many characteristics. This may be summarised as 
follows (Fischer & Emans, 2000; Goldstein & Thomas, 2004; Kermode, 2006; Ma et al., 
2003; Stoger et al., 2002): 
 
Ccc – Cb = 1000 – 50 = βn*(kcc – kb) = βn [  Δ Cost/storage 
 Δ Distribution 
 Δ Gene size 
 Δ Glycosylation 
 Δ Multimeric protein assembly 
 Δ Production cost 
 Δ Production scale 
 Δ Production vehicle 
 Δ Propagation 
 Δ Protein folding accuracy 
 Δ Protein homogeneity 
 Δ Protein yield 
 Δ Public perception of risk 
 Δ Safety 
 Δ Scale-up costs 
 Δ Therapeutic risk 
 Δ Time required 
 Δ Uncertainty] 
 
The benefit of this approach is to help ultimately to understand the specific differences 
between production methods and consider how those differences contribute to the cost 
differences from biopharming. 
 
3.3 Imperfect competition 
The cost of developing a biopharmaceutical has been estimated at US$1.2 billion (DiMasi, 
forthcoming). This amount pays for the technical development as well as moving the 
compound through successful clinical trials and securing regulatory approval for the 
compound. It is a fixed cost borne by the owner of the technology, a cost that must be 
recouped in order for a biopharmaceutical to be profitable. However, economic theory focuses 
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on the marginal cost of production as the main determinant of market price; fixed costs, 
particularly sunk costs, do not figure in calculations of marginal costs and thus price in a 
competitive market. 
In order to allow the developer the opportunity to recoup these fixed costs, the government 
grants a temporary monopoly in the form of a patent. A monopoly reduces net social welfare 
by constraining supply of a product and raising its price. However, in the absence of an ability 
to raise the price of a biopharmaceutical above its marginal cost of production, the developer 
would not be able to recoup the development costs. If developers could not recoup these costs, 
they would cease to invest in developing new biopharmaceuticals. Thus, the granting of 
patents provides an incentive to invest in research and development that can be profitable over 
the medium term. Economists do discuss whether this institutional arrangement is better than 
alternative arrangements from the standpoint of social welfare. 
To complicate the analysis of biopharmaceuticals, the situation in the industry is more like an 
oligopoly than a monopoly. In a monopoly, there is one supplier of the product. In an 
oligopoly, several firms sell products that are more or less similar. These firms may compete 
on price, quantity, or product qualities, depending on the specific model of oligopoly. 
Biopharming, as discussed above, is pursuing the production of existing pharmaceutical 
compounds but in a novel way. Thus, the product itself is potentially not unique. If it is not 
unique, then firms appear to be engaged in an oligopolistic competition based on price with 
potentially weakly differentiated products. The theoretical issue is complicated by the issue 
that the innovating firm has rights to a production technology that is potentially more efficient 
than its competitors. This issue suggests that competition could be price-based, but does raise 
the potential for excess profits as a result of the proprietary technology. 
 
3.4 Demand for biopharming products 
An important consideration is the impact of biopharming on the rest of New Zealand’s 
agricultural and tourism industries. This depends on consumers in overseas markets. Some of 
the specific issues are: size of consumer segments; estimates of market size, given current 
purchases of agricultural products and consumer scepticism regarding biotech; and price 
impacts, again given current commodity prices, price trends, and consumer perceptions. Some 
specific questions relating to demand are listed below. 
Markets for the commodity 
• What are the intended markets for the commodity, by country and by market segment? 
• What market share does NZ have, and how might this be affected? 
• What are the trends in those markets, such as changes in tastes, income per capita, etc.? 
• What is the elasticity of demand in those markets, that is, how sensitive are consumers 
to changes in price? 
• What are NZ’s competitors doing, and what impacts could they have? 
The GMO/biotech issue 
• How sensitive are the proposed markets to the issue of genetic modification? 
• What proportion of the markets is particularly sensitive to the GM issue? 
• Have any estimates been made of the likely discount facing GM products in the 
markets? 
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• Are ‘gatekeeper’ effects likely to exist? What is the level of concentration of food 
wholesalers, distributors and retailers in the market for the commodity? 
• What are the requirements for labelling of GM products? 
• What proportion of NZ’s exports are exposed to these labelling requirements? 
• What costs will be incurred complying with labelling and other regulations? 
• What are competitors doing regarding GM and biopharming? 
 
3.5 Risk and uncertainty 
Special consideration should be given to the idea of uncertainty. The uncertainty identified in 
the literature is technical, regulatory, and political. The Constructive Conversations project is 
specifically focused on regulatory aspects and potential impacts on the environment, health, 
and the economy. It is concerned with actual environments and practices that would be part of 
a biopharming system, especially with experiential knowledge regarding those environments 
and practices. 
If the foregoing review has highlighted anything, it is that the economic impacts of 
commercial release of biotech products are uncertain and potentially very complex. The 
uncertainty and complexity make identifying risk evaluation criteria difficult. The following 
discussion should be seen in this light and should not be taken as exhaustive or predictive. 
One way to think of risk is as the probability of an occurrence multiplied by its size or 
importance. This characterisation has been demonstrated to be incomplete, especially when 
discussing perceptions of risk (see, for example, Slovic, 2000). This incomplete formula is 
adopted here only as a starting point. 
The second mental construct to consider is concentric circles (we are indebted to Tere 
Satterfield, Decision Research, for this observation). Each product, each crop, can be thought 
of as the centre of a set of concentric circles moving outward from related crops to the 
particular agricultural sector to wider categories up to the level of national effects. 
In evaluating the risk posed by a particular application of genetic technology, it will be 
important to consider the probability of adverse reactions and the value of the sectors affected. 
Adverse reactions can come in different forms. For example, it may be that consumer 
reactions to a product are quite strong. On the other hand, the reaction might come from 
market gatekeepers, regardless of direct consumer reaction. Reactions in one market might be 
non-existent, but strong in another. The value of the sectors potentially affected is also hard to 
determine beforehand. A specific product is contained in many concentric circles, and 
although a biotech product may be intended for restricted use, it may be related or linked to 
products of much wider commercial importance. 
There are some stylised facts to bear in mind: 
• New Zealand’s largest export markets are: Australia, the US, the EU (ex. UK), Japan, 
and the UK. 
• New Zealand’s largest exports are: Dairy, Meat, Wood, Fruit & Vegetables (combined), 
and Fish. 
• Europeans are more sceptical than North Americans regarding GM. 
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• Cost-reducing GM products are much less valuable than consumer-oriented products. 
• Consumers are sensitive to different types of genetic technologies, with food 
applications less acceptable than medical one, and transgenics less acceptable than other 
genetic technologies. 
• The importance of New Zealand’s image abroad is not well understood and needs more 
study. 
• The sensitivity to consumers of cross-product GM ‘contamination’ is not well 
understood. 
From these stylised facts a couple of observations can be made: 
• Commercial release of a medically-oriented GMO that is unrelated to any of New 
Zealand’s important exports, especially if it is not a transgenic organism, is potentially 
less risky. 
• Commercial release of a food GMO, such as functional food, that will affect any of 
New Zealand’s major products or markets (especially Europe) has a high probability of 
causing an adverse effect and can potentially affect large parts of the country’s exports, 
so that it is overall probably more risky. 
In addition, there is a body of research on risk perception that is outside the economic 
expertise at the AERU. Briefly, risks are perceptually evaluated not just on a ‘probability 
times size’ basis, but also on criteria such as control, dread, equity, certainty, voluntariness, 
etc. These perceptions of risk affect consumers and researchers alike. 
One important concept from this literature is ‘stigma’. It is possible for products to be 
stigmatised; producers and even countries can be similarly affected. One common example is 
the stigma that affected Johnson & Johnson as a result of the Tylenol poisonings. Another 
example is the possibility that Las Vegas tourism could be stigmatised by the siting of a 
nuclear waste storage facility in the same state, Nevada. Risk researchers have developed 
methods for assessing susceptibility to stigma and for considering its wider impact. Good 
resources for more information are Slovic (2000) and Flynn, Slovic, and Kunreuther (2001). 
 
3.6 Conclusion 
This chapter has quickly covered a wide range of economic theory. Biopharming products, 
whether functional foods, nutraceuticals, or bipharmaceuticals, will have both supply and 
demand effects. On the demand side, consumers will judge not only the biopharming product 
but also potentially a number of related products. On the supply side, it will be important to 
consider cost of production as well as industry structure. Finally, all of the available 
information represents a current approximation. All of the economic calculations are subject 
to the influences of risk and uncertainty. 
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Chapter 4 
Analysis of Potential Impacts 
 
 
4.1 Production through biopharming 
The model set out earlier requires data to be estimated. The data that are available are not 
numbers, but descriptors. From the literature, the difference in cell culture and biopharming as 
method of production can be stated as follows: 
 
= βn  [ Cost/storage:  Expensive ? Cheap 
 Distribution:  Difficult ? Easy 
 Gene size:  Limited ? Not limited 
 Glycosylation:  Correct ? Correct? 
 Multimeric protein assembly:  No ? Yes 
 Production cost:  High ? Low 
 Production scale:  Limited ? Worldwide 
 Production vehicle:  0 
 Propagation:  Hard ? Easy 
 Protein folding accuracy:  High ? High? 
 Protein homogeneity:  Medium ? High? 
 Protein yield:  Medium-high ? High 
 Public perception of risk:  Medium ? High 
 Safety:  Medium ? High 
 Scale-up costs:  High ? Low 
 Therapeutic risk:  Yes ? Unknown 
 Time required:  High ? Medium 
 Uncertainty:  Current ? Unknown]. 
 
The difference vector indicates that the biopharmed compounds are different to the cell 
culture compounds on nearly every dimension investigated. The differences fall into several 
categories. The first category is those dimensions that are cost-related and quantifiable, e.g., 
production cost and protein yield. Biopharming tends to outperform cell culture on most of 
these dimensions. Biopharming’s success on these criteria appears to be driving the cost 
estimates that biopharmed compounds will be one-twentieth or less of the cost of current 
production techniques. The second category is those dimensions in which the results of 
biopharming are unknown. In the difference vector, these dimensions are those with a 
question mark (?) or labelled ‘unknown’, such as protein folding accuracy and protein 
homogeneity. A third category contains those dimensions whose values are known but 
qualitative. Because the differences are expressed qualitatively, there is insufficient 
information to generate an economic analysis. Thus, it is difficult to put on value on 
‘medium’ safety versus ‘high’ safety. Finally, the risk profile of biopharming is, according to 
the difference vector, a potential concern. One risk dimension, public perception of risk, is 
worse for biopharming than for cell culture. The other risk dimension, therapeutic risk, is 
unknown. 
The result of this model of biopharming, in which production is viewed as a bundle of 
dimensions with independent contributions to the cost of production, is that current 
information is insufficient. Some dimensions, particularly the quantitative cost dimension, 
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have received attention and are favourable for biopharming. Other dimensions are still largely 
qualitative and even unknown. Finally, there is insufficient information to determine the 
values of the betas, which indicate the contribution of each dimension to the final price of the 
compound. That is, the monetary impact of, for example, glycosylation versus worldwide 
distribution capacity is undetermined. As a result, the full cost of commercialised biopharmed 
therapeutic proteins, taking into account the technical differences, risks, and uncertainties, 
cannot be properly estimated from current data. 
In addition, this model applies only to the biopharming product itself; it does not account for 
the concentric rings of influence into other industries. The theoretical model and other 
economic theory are applied below to two examples. One example is the production of 
lactoferrin in milk, and the other is low-GI (glycaemic index) potatoes. 
 
4.2 Lactoferrin in milk 
Lactoferrin is a protein produced by mammals and found in milk and even tears 
(www.pharming.com). It is a product that has considerable health benefits including 
positively affecting the immune system, proven ability to fight bacteria that cause eye and 
lung infections and limiting cancer growth in cells. There is still research being conducted on 
further benefits that could be provided by lactoferrin. 
The world market for lactoferrin in 2004 was 90 metric tonnes per year and appears to be 
growing in global interest (AP-foodtechnology.com, 2004). The reported price for lactoferrin 
is at least US$300 per kilogram, making the worldwide market valued at approximately 
US$27 million per year. Fonterra reported that it is participating in the lactoferrin market with 
a new plant in Hautapu (Fonterra, 2005). 
Presently, lactoferrin is extracted from cow’s milk and added to food products, such as infant 
formula and yoghurt. Research has pursued producing a human version of lactoferrin in non-
human organisms. The resulting product could be a functional food, nutraceutical, or 
biopharmaceutical, depending on how much the developing firm invests in following the 
regulatory process. Also, as a GMO product, it may require labelling. 
Biopharming research has produced recombinant human lactoferrin (rhLF) in rice by Applied 
Phytologics and Ventria Bioscience. The company Agennix has announced that its microbial 
fermentation processes can produce lactoferrin too, and has production costs that were equal 
to the Ventria Bioscience biopharm rice (Wisner, 2005a). Meristem Therapeutics and 
Washington State University have also done research on lactoferrin production, but it is 
unclear as to the exact organisms used. Other research has produced rhLF in the milk of cows 
and mice (van Berkel et al., 2002). 
Scientific research on rhLF provides information relating to some of the dimensions discussed 
above (Thomassen, van Venn, van Berket, Nuijens, & Abrahams, 2005; van Berkel et al., 
2002). The protein structure appears similar to natural human lactoferrin (hLF) (Thomassen et 
al., 2005). The rhLF and hLF appear to be functionally similar, and to be safe in animal trials 
(van Berkel et al., 2002). The rhLF is also expressed at high concentration in cows’ milk (van 
Berkel et al., 2002). This research thus seems to have determined that rhLF is physically 
similar to hLF, and that the protein yield may be commercially sufficient. Some dimensions 
for which information did not appear available and which are therefore continuing sources of 
uncertainty are: production cost, production scale, production vehicle, public perception of 
‘risk’, scale up costs, time required. 
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A further issue with rhLF is that this scientific research has compared the human and 
recombinant human versions. From a business perspective, however, the comparison of 
bovine lactoferrin and rhLF is also germane. These two types of lactoferrin could be 
competing products in the marketplace. It is thus important to know whether the rhLF has any 
therapeutic benefits over the bovine version, and what the comparative costs of producing it 
are. One central question is the cost-benefit assessment of the two products. The information 
available is insufficient to make this assessment. 
Furthermore, the rhLF has the further complication of the uncertainty surrounding consumer 
reactions to GM technology. If there are no adverse reactions, then the simple cost-benefit 
analysis suggested above would be sufficient to assess the business case. However, the 
research reviewed above indicates that there are adverse consumer reactions; the question thus 
becomes the extent and longevity of these reactions. Using the figures cited earlier regarding 
adverse reactions to GMOs (Sanderson et al., 2003) (27 per cent of Australians, 20 per cent of 
US citizens, and 30 per cent of Britons opposed to the use of GMOs) and figures on exports 
from 2002, the potential losses in these three markets from consumer rejection of New 
Zealand dairy products because of the introduction of a GMO into the dairy sector are 
NZ$348.5 million per year. This figure does not include any price discounts that other 
consumers might demand, markets other than those three countries, or exports other than 
dairy products. 
A similar calculation can be made of impacts on tourism. The same research found that nine 
per cent of Australians, five per cent of US citizens, and six per cent of Britons would stop 
visiting New Zealand if a GMO were introduced into the environment. Using tourism 
spending figures for these countries from the New Zealand Tourism Board, the potential 
losses in tourism amount to NZ$191.1 million per year. 
This analysis suggests several things. First, all the necessary business information to assess 
the economic potential of producing recombinant human lactoferrin in milk in New Zealand is 
not available. Any assessment at this stage is necessarily preliminary. Secondly, it will be 
difficult to earn more than an economically normal profit by developing and marketing rhLF. 
There seem to be several close substitutes and competing technologies, so there appears to be 
little opportunity to create a dominant position in the market and earn oligopoly or monopoly 
profits. Finally, social science research suggests that introducing a GMO into the New 
Zealand dairy sector has a potential to cause a minimum of NZ$539.6 million in losses to the 
dairy and tourism industries. Thus, such a biopharming endeavour would need to offset those 
losses before it could be viewed as a net positive for the New Zealand economy. Given that 
sales of lactoferrin are currently in the tens of millions of US dollars, offsetting hundreds of 
millions of NZ dollars of lost exports seems unlikely in the short to medium term. 
 
4.3 Low-GI potatoes 
The glycaemic index (GI) measures the amount and speed at which different food types raise 
blood sugar levels. Foods with high GI ratings raise blood sugar levels quickly, making them 
potentially unsuitable for people with diabetes . Concern about GI ratings has also spilled out 
into the general public. The Human Nutrition Unit at the University of Sydney noted that ‘the 
World Health Organisation (WHO) and Food and Agriculture Organisation (FAO) 
recommended that people in industrialised countries base their diets on low-GI foods in order 
to prevent the most common diseases of affluence, such as coronary heart disease, diabetes 
and obesity’ (Glycemic Index Research, 2006). Links have also been drawn between low-GI 
diets and low-carbohydrate diets, such as the Atkins diet. 
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The value of the market for such foods with perceived health values is difficult to state. 
Euromonitor estimated the 2005 total world values of sales of naturally healthy, high-fibre 
foods at US$25 billion (Euromonitor, 2006). Other research found estimated sales of 
functional and fortified foods in the United States in 2006 at US$35.86 billion (Sloan, 2006). 
Low-GI foods are a growing sector of the functional foods market (Sloan, 2006). 
The GI rates foods on a scale from 0 to 100, with higher ratings indicating that foods have 
greater impacts on blood sugar levels (Glycemic Index Research, 2006). Potatoes can have a 
range of GI ratings, depending on the source of the potato and preparation methods; some 
data from the University of Sydney on potato GI results are presented in Table 4. However, 
potatoes are not a processed food whose ingredients can be modified to lower the GI. Thus, a 
lower GI must result from modifying the potato itself. 
A low-GI potato could replace some current potatoes and potato products. Low-GI potatoes, 
which might be produced through GM technology, would be a functional food rather than a 
biopharmaceutical or nutraceutical product. It could appeal to consumers who are currently 
wary of standard potatoes. It could also keep consumers eating potato products even as they 
become more concerned about GI. Impacts are thus defensive (preventing erosion of market 
share) and expansionary. 
The current world market for potatoes is $40 billion (FAO, 2006); New Zealand produces 
500,000 tonnes of potatoes and has export sales of $69.3 million in fresh and frozen potatoes 
for 2005 (HortResearch, 2005). 
New Zealand also has scientific expertise in the area of potato research (Collins, 2003), so 
that the low-GI potato could be developed here. There are existing examples of proprietary 
control of a Plant Variety Rights that can provide suggestion for how such a new potato could 
be developed and marketed. One example is the Gold kiwifruit developed by HortResearch 
and controlled by ZESPRI. The growing of this cultivar has been tightly controlled in order to 
maintain good fruit quality and good prices for growers. The cultivar has also been planted in 
both Northern and Southern hemispheres to produce a year-round supply. As a result, Zespri 
has been able to deal with cultivation and quality issues and earn profits from proprietary 
control of the cultivar. A second example is the Jazz apple, a proprietary cross of Royal Gala 
and Braeburn. Commercial development of the cultivar is controlled by ENZA. The 
organisation has contracted growers in both hemispheres to produce Jazz, which enables year-
round supply but also keeps profits from the cultivars flowing to New Zealand. The new 
variety is expected to yield an internal rate of return on the investment in research and 
development of 13 per cent by 2009, yielding a net present value of $2.8 million (Growing 
Futures, 2005). 
The model developed above for assessing biopharming provides useful information on low-
GI potatoes. A number of the dimensions in the model concerned the specific proteins to be 
extracted from biopharmed crops. Because low-GI potatoes would be a functional food, many 
of these dimensions are moot. The issues surrounding this product are thus simpler. Some of 
the dimensions that would require assessment as the product is developed and marketed are 
cost/storage, distribution networks, production cost, production scale, propagation, public 
perception of risk, safety, time required, and uncertainty. 
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Table 4: GI Results for potatoes 
Specific potato tested GI Serving size (grams) 
Potato, Ontario, white, baked in skin (Canada) 60 150 
Potato, Russet Burbank, baked without fat (Canada) 56 150 
Potato, Russet Burbank, baked without fat, 45-60 min (USA) 78 150 
Potato, Russet Burbank, baked without fat (USA) 94 200 
Potato, Russet Burbank, baked without fat (USA) 111 150 
Potato, Desiree, peeled, boiled 35 min (Australia) 101 150 
Potato, Nadine, boiled (New Zealand) 70 150 
Potato, Ontario, white, peeled, cut into cubes, boiled in salted water 
15 min (Canada) 58 150 
Potato, Pontiac, peeled, boiled whole for 30 min (Australia) 56 150 
Potato, Pontiac, peeled, boiled 35 min (Australia) 88 150 
Potato, Prince Edward Island, peeled, cubed, boiled in salted water 
15 min (Canada) 63 150 
Potato, Sebago, peeled, boiled 35 min (Australia) 87 150 
Potato, uspecified type (Kenya, Africa) 24 150 
Potato, white, cooked (Romania) 41 150 
Potato, white, boiled (Canada) 54 150 
Potato, boiled (Australia) 56 150 
Potato, boiled in salted water (India) 76 150 
Source: GI Database (2007) 
 
 
Overall, the total economic potential of low-GI potatoes is uncertain at present. The product 
could have clear consumer appeal in the functional foods market, a multibillion dollar and 
expanding market segment (Sloan, 2006). As a functional food, it would have lower 
regulatory hurdles than a biopharmaceutical. Furthermore, potatoes are a commonly 
consumed food, and the total market is again a multi-billion dollar market. A final positive 
factor is that New Zealand has scientific expertise in the area and business experience in 
creating profits from Plant Variety Rights. 
There are potentially difficulties, however. The GM status of the product could create 
problems in some markets, in terms of both meeting food safety and regulatory requirements 
and responding to consumer concerns. As with the earlier example of producing rhLF in milk, 
there is the risk of losing at least NZ$191.1 million in annual tourism earnings. There would 
also be a risk of losing some export earnings from potato exports (total exports, NZ$69.3 
million). Whether earnings from other horticulture products or other agricultural exports 
would be affected is unknown. Other difficulties arise from the risks and uncertainties that 
exist for biopharming products. Finally, it is unknown at this point what competing products 
would be developed, either other types of low-GI potatoes, other low-GI foods, and even 
other dietary trends. 
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Chapter 5 
Conclusion 
 
 
This report has presented preliminary research into the economics of biopharming. The 
research has covered a wide range of economic theory and sources of data. The main reason 
to cover so much ground is that definitive information on the economics of biopharming is 
scant. Thus, this research has looked to economic theories of supply and demand, consumer 
behaviour, and industry structure; assessments of the impacts of prior biotechnologies; and 
the information that is available on biopharming. All of these elements together underpin the 
present assessment of biopharming. 
This report has organised its assessment around a model or framework derived from the 
literature on biopharming. The potential impacts of biopharming are a function of the benefits 
and costs from changing from one type of production system to another, coupled with product 
advantages that the new system might afford. Clearly, there are a number of dimensions on 
which production systems differ. The impact of biopharming in its broad sense, including 
biopharmaceuticals, nutraceuticals, and functional foods, depends on how each of these 
dimensions changes and how those dimensions contribute to the value of the products. 
This report has also considered two specific products: lactoferrin in milk and low-GI potatoes. 
The main result from this examination is that the necessary information to develop a robust 
economic analysis of these products is lacking. Much of the information on the relevant 
dimensions is simply unknown. A second result from this work is that the potential value of 
these products varies tremendously, depending on the overall size of the potential market, 
control of technology or proprietary information, and other factors. A third concern is adverse 
reactions in overseas markets. The future impact of consumer concerns is uncertain and 
contested. Nevertheless, since available information on adverse reactions suggests that the 
economic impact could be large compared to earnings from novel products, it is important to 
understand these potential reactions. 
This has been a preliminary piece of research. As more information becomes available on the 
potential products, the economics of their production, and consumer demand for them, this 
area of research will be able to improve the estimates of the economic impacts of biopharming 
in New Zealand. 
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Appendix 
 
 
Table A1: Transgenic plant biopharming companies and products 
Company Plant Drug Comments 
Agracetus Corn   
Agragen Pharma flax Medicines for trauma patients who need a 
blood transfusion. 
 
AltaGen Potato Hemoglobin. 
Factor VIII; human growth hormone. 
 
Applied Phytologics Rice Human -1- antitrypsin Dirgent protein - 
origin: Forsythia intermedia. 
Laccase - origin: Forsythia intermedia. 
Lactoferrin - origin: human. 
Lysozyme - origin: human. 
Pinoresinol-lariciresinol reductase - origin: 
Forsythia intermedia. 
Secoisolariciresinol dehydrogenase  
NptII*. 
Hygromycin phosphotransferase* - origin: 
E. coli. 
Antithrombin - origin: human. 
Aminoglycoside 3'- adenylyltransferase - 
origin: human. 
Serum albumin - origin: human. 
Human -1- antitrypsin is a protein of therapeutic potential in cystic 
fibrosis, liver disease and hemorrhages. 
Biolex Duckweed  -interferon and other proteins. Investigational new drug (IND) filing this year. 
Biolex Inc 
 
Lemna (duckweed)  Locteron (controlled-release -interferon for hepatitis B and C), 
completed Phase 1; fibrinolytic clot buster, preclinical. 
Biosource Tobacco mosaic virus 
Tobacco etch virus 
Phytoene synthase - origin: tomato. 
Trichosanthin - origin: Trichosanthes 
kirilowii. 
Alpha-amylase - origin: rice. 
Alpha-hemoglobin - origin: rice. 
Beta-hemoglobin - origin: human. 
Trichosanthin - origin: Trichosanthes 
kirilowii. 
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Company Plant Drug Comments 
Biosource Technologies  and 
Stanford University 
 
Plant virus based 
transient expression 
system 
 Developed a technology to produce a tumor specific vaccine for 
the treatment of malignancies. 
Biosource Technologies is now named the Large Scale Biology 
Corporation. 
Boyce Thompson Potatoes Hepatitis B.  
Chlorogen, Inc Tobacco chloroplasts Cholera vaccine. 
Human serum albumin. 
Interferon (hepatitis C). 
TGF-ß for treatment of ovarian cancer. 
Animal vaccines. 
 
Cobento Arabidopsis Thaliana Human intrinsic factor (rhIF for 
diagnostics), in market 
rhIF plus vitamin B12 for B12 deficiency, in 
clinical trails. 
 
Cornell University Potato Edible vaccine for Hepatitis B.  
Crop Tech Tobacco Confidential business info; origin: human. 
NptII*. 
Filed for bankruptcy in 2003. 
CropTech Corp and 
Prodigene- Cramer 
Maize Avidin. 
β-glucuronidase. 
Mechanical gene activation (MeGA) system that was developed. 
First commercial molecular-farming venture. 
Dow 
(Dow Plant Pharmaceuticals) 
(DowPharma) 
Corn Phosphinothricin acetyl transferase*. 
Confidential business information - origin: 
human. 
 
 A plant-based vaccine To protect poultry from Newcastle disease 
virus (NDV). 
Was approved by the USDA-APHIS’ Center for Veterinary 
Biologics in 2006. 
 Beans of castor plants RiVax. Dow offers contract development and manufacturing of proteins 
in transgenic plants. 
RiVax was developed to protect against exposure to ricin toxin. 
Dow AgroSciences Maize  Described an adenosine deaminase selection system. 
 Non-nicotine tobacco 
plant cell culture 
Newcastle disease vaccine for poultry. Approved by USDA 2/2006. 
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Company Plant Drug Comments 
Emlay and Associates Safflower Growth hormone* - origin: carp. Oleosin* - 
origin: Arabidopsis thaliana. 
Phosphinothricin acetyl transferase. 
 
EpiCyte Corn 
Maize/rice Transgenic 
soybean 
Chinese hamster ovary 
(CHO) cells 
Monoclonal antibodies (plantibodies). 
EPI19 (bronchonliotis/pneumonia in 
infants).. 
 
 
A full-length humanized IgG1 that recognizes herpes simplex 
virus (HSV)-2 glycoprotein B has been expressed in. This 
antibody, along with an IgG that recognizes the R9 protein of 
respiratory syncitial virus. 
EPIcyte pharmaceuticals and 
ProdiGene 
Plants Antibodies.  
Farmacule BioIndustries Tabacco 
Sugarcane 
Virtonectin. Available in late 2006-early 2007; proteases. 
Garst Corn Acetolactate synthase*, confidential 
business information - origin: human and 
mouse. 
 
Greenovation Biotech  Moss Humanization of glycosylation. Homologous recombination in moss allows for easier engineering 
of strains. 
Greenovation Inc., Freiburg The moss 
Physcomitrella 
  
Guardian Biotechnologies Canola 
Oriental Melon 
Poultry vaccine for coccidiosis. Phase 2. 
Hawaii Agriculture Research 
Center 
Sugarcane Confidential business info; origin: human.  
Horan Bros. Agri. Enterprises Corn NptII*.  
Iowa State University Corn NptII*. Enterotoxin subunit B - origin: E. 
coli. 
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Company Plant Drug Comments 
Large Scale Biology Corp Tobacco mosaic virus   
 Tobacco Non-Hodgkin lymphoma vaccine  
Alpha galactosidase. 
Completed phase 1. 
For Fabry disease in clinical trails. 
 Tobacco B-Cell non-Hodgkin’s lymphoma (Phase 
III). 
Alpha-galactosidase A (therapy for Fabry’s 
disease). 
Patient-specific cancer vaccines. 
Hepatitis B surface antigen, scFvs and other 
recombinant proteins. 
The antibodies were produced using virus-infected plants rather 
than transgenic plants, which is a strategy that is well suited to the 
rapid and small-scale production that is required to treat individual 
patients with unique antibodies. 
Has completed phase I trials. 
Limagrain Corn Phosphinothricin acetyl transferase*. 
Procollagen - origin : human. 
G glycoprotein Serum albumin - origin: 
human. 
Alpha-hemoglobin - origin: human. 
Beta-hemoglobin - origin: human. 
 
Medicago Alfalfa Hemoglobin  
Meristem Therapeutics  Corn 
Tobacco 
Maize 
Alfalfa 
Gastric lipase  
Hemoglobin;gastric lipase (cystic fibrosis, 
pancreatitis; Phase II). 
Albumin (surgery). 
Cancer therapeutic antibodies. 
Meripase (cystic fibrosis and lipid-storage 
disordes). 
Lactoferrin (gastrointestinal disorders). 
To treat pancreatic insufficiency associated with cystic fibrosis in 
phase 2a. 
Meripase is in field trials and testing. 
Lactoferrin is in phase 1. 
Monsanto  Soybean IgG anti-herpes simplex virus.  
 Corn C transcriptional activator.  
MPB Cologne GmbH Potato 
Rapeseed 
Antibody.  For detection of food/water borne pathogens. 
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Company Plant Drug Comments 
Nexgen Biotechnologies Potato 
Cucumber 
Oriental Melo 
Tobacco 
Thyroid-stimulating hormone receptor. 
Hemorrhagic fever virus antigens for 
diagnosis. 
Poultry vaccine for avian influenza (H5N1), 
epidermal growth factor, albumin fusion 
protein. 
Thyroid-stimulating hormone receptor (diagnosis of Graves 
disease), projected marketed in 2006. 
Noble Foundation Alfalfa NptII*. 
Cholera toxin B - origin: Vibrio cholera. 
 
Phytomedics Tobacco  Manufacturing process secretes biologics from roots. Current 
product focus on plant extracts. 
Pioneer Rapeseed Phosphinothricin acetyl transferase* - origin: 
Strep. hygroscopicus. 
 
Planet Biotechnology  Tobacco CaroRx. 
RhinoRx. 
Antibodies- SIgA anti-S. mutans. 
Anti-Streptococcus mutans secretary IgA 
(SIgA) plantibody. 
Streptococcus mutans specific Guy’s-13 
antibody, which prevents dental caries. 
CaroRx, proteins for tooth decay, in phase 2. 
RhinoRx, for common cold, in preclinical testing. 
Anti-Streptococcus mutans secretary IgA (SIgA) plantibody 
currently in phase II clinical trials for the prevention of dental 
caries. 
The first clinical trial of plant-based immunotherapy was by this 
company. 
This company has compared the cost per gram of purified IgA 
made by cell culture, transgenic goats, grain (7.5 tonne ha−1) and 
green biomass (120.0 tonne ha−1). Expression levels will have a 
significant impact on the costs but, at the best expression level 
reported [500 μg g−1 leaf for a secretory IgA, the final cost should 
be well below US$50 g−1. This significantly undercuts the costs 
of cell culture (US$1000 g−1) or transgenic animal production 
systems (US$100 g−1). The biggest component of cost with 
plantibodies will be purification. 
Protalix Plant cell culture Glucocerebrosidase. 
Fully humanized IgG. 
Glucocerebrosidase for Gaucher disease is in Phase 1. 
Fully humanized IgG is in preclinical development. 
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Company Plant Drug Comments 
ProdiGene Corn 
Maize 
Antibody for Traveler’s diarhea 
Trypsin. 
laccase. 
Subunit vaccines, recombinant antibodies 
and further technical enzymes, such as 
aprotinin and laccase. 
Recombinant bioactive avidin and ß-
glucuronidase. 
Antibody for Traveler’s diarrhoea completed phase 1. 
Trypsin which is produced using bovine DNA, is being marketed 
by Sigma Aldrich under the trademark name of TrypZean. 
Laccase which acts on lignine and could have applications in 
paper and textile production. 
This company demonstrated that feeding pigs an edible maize 
vaccine protects them from the transmissible gastroenteritis virus 
(TGEV). 
This company is an industry leader in cereal-based commercial 
protein. 
Recombinant bioactive avidin and ß -glucuronidase are the first 
recombinant plant-derived proteins to be produced commercially 
made by Prodigene Inc and sold by Sigma Chemical company. 
 Corn Phosphinothricin acetyl transferase*. 
Aprotinin - origin: pig. 
Surface antigen - origin: Hepatitis virus B. 
Surface antigen - origin: transmissible 
gastroenteritis virus. 
gp120 (glycoprotein 120) - origin: simian 
immunodeficiency virus. 
Enterotoxin subunit B - origin: E. coli. 
NptII*. 
Phosphinothricin acetyl transferase*. 
Aprotinin - origin: Bos taurus. Enterotoxin 
subunit B - origin: E. coli. 
Surface antigen - origin: Hepatitis virus B.  
 
 Tomato NptII*.  
ProdiGene and EPIcyte 
Pharmaceuticals (strategic 
partnership) 
Corn antibodies.  
RJ Reynolds Tobacco mosaic virus   
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Company Plant Drug Comments 
SemBioSys Safflower Antiobesity peptid; somatotropein 
Insulin. 
Apoplipoprotein A-1. 
Immunospheres. 
Safflower is now being grown on a trial basis in Chile, US & 
Canada (Levinson, 2007). 
 Transgenic oilseed 
Canola, (Brassica 
napus) 
Human insulin and apolipoprotein in 
preclinical development. 
Hirudin. 
The oleosin-fusion platform developed, in which the target 
recombinant protein is expressed in oilseed rape or safflower as a 
fusion with oleosin. 
Spanz 
 
Potatoes Make proteins that will help the body repair 
itself after heart or circulatory system 
surgery or nervous diseases. 
Spanz (Singapore and NZ) Biotech the 50-50 “biopharming” 
venture. 
Have since ceased operations. 
U of Kentucky Tobacco Confidential business info; origin: human 
and mouse. 
 
UniCrop Oilseed technology 
platform 
 The idea is to isolate recombinant proteins from the rapidly 
developing sprouts cultivated in bioreactors. 
Ventria Bioscience 
 
Rice Product for iron deficieny and acute 
pediatric diarrhea in safety testing. 
Targeting Lactoferrin and lysozyme. 
Have been conducting field trials, growing GM rice as a means for 
producing food additives with medical uses. 
Virginia Tech and State 
University and CropTech; 
Cramer and colleagues. 
Transgenic tobacco Glucocerebrosidase production. Their studies ‘strongly support’ the future commercial viability of 
transgenic plants for the production of glucocerebrosidase, and of 
other lysosomal enzymes, for enzyme replacement therapy. 
Washington State University Barley Green fluorescent protein*. Phosphinothricin 
acetyl transferase*. 
Amylase - origin: barley. Antithrombin - 
origin: human. 
Antitrypsin - origin: human. Lactoferrin - 
origin: human. Lysozyme - origin: human. 
Serum albumin - origin: human. 
 
Sources: (Cline, 2006; Collins, 2003; Colorado State University, n.d.; Daniell et al., 2001; DOR BioPharma Inc, 2006; Drabenstott, 2002; Elbehri, 2005; Fischer & Emans, 2000; Fischer, 
Stoger, Schillberg, Christou, & Twyman, 2004; Fox, 2006; GianCarlo, 2006; Giddings, Allison, Brooks, & Carter, 2000; Keefer, 2004; Larrick & Thomas, 2001; Leake, 2006; Leske, 2006; 
Levinson, 2007; Ma, Drake, & Christou, 2003; Schoebi, 2005; Tae-Gyu, 2006; Thiel, 2004; Wisner, 2005). 
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Table A2: Transgenic animal biopharming companies and products 
Company Animal Drug Comments 
Avian Initiative Transgenic chicken 
eggs 
Recombinant proteins. Avian Initiative is a collaboration between Viragen and the Roslin 
Institut.e 
AviGenics Chicken eggs Recombinant proteins.  
BioProtein Technologies  Transgenic rabbits Recombinant proteins.  
Ecoarray  Transgenic fish Recombinant human Factor VII Ecoarray was formerly AquaGene. 
Genzyme Transgenics  Goat herds Tumor necrosis inhibitory monoclonal 
antibody, Remicade. 
Remicade is marketed by Centocor for the treatment of inflammatory 
conditions, including Crohn’s disease and rheumatoid arthritis. 
General growth hormone. 
Genzyme Transgenics and 
Genzyme 
Goats milk Antithrombin III. The protein is currently in phase III clinical trials to prevent blood 
clotting during cardiac surgery in heparin-resistant patients. 
GTC Biotherapeutics, Inc Transgenic goats ATryn (antithrombin III)  
Monoclonal antibodies. 
Malaria vaccine. 
European Medicines Agency (EMEA) decided to recommend 
approval of ATryn for people with a rare inherited disease that leads 
to blood clotting. 
 Cattle Human serum albumin.  
 Milk of transgenic 
goats 
MM-093. For people suffering from autoimmune disorders, such as rheumatoid 
arthritis, psoriasis or multiple sclerosis. 
  ATryn. The pioneering drug, an anti-clotting agent for people with a rare 
inherited disease that was developed to treat patients with hereditary 
antithrombin deficiency (HAD), which makes people vulnerable to 
deep-vein thrombosis. 
Gyeongsang National University. 
Professor Kim Jin-hoi and a team 
of researchers. 
Genetically 
engineered mice 
Erythoprotein, the growth factor in 
blood. 
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Company Animal Drug Comments 
Hematech Cattle Human polyclonal antibodies 
(vaccines). 
 
Cattle that have, in addition to their own genome, an extra artificial 
minichromosome that contains genes for human immunoglobulins. 
Hermatech plans to use this technique to produce polyclonal human 
antibodies against a number of antigens, including anthrax. 
Infigen Inc   Protein production.  
Nexia Biotechnologies  Transgenic goats  Protexia (human butyrylcholinesterase) 
Spider silk protein. 
Protexia in preclinical development as a potential protectant against 
nerve gas. 
Origen Therapeutics  Chicken eggs Human poly- and monoclonal 
antibodies for therapeutic purposes. 
 
Pharming Transgenic rabbits 
Cows 
Recombinant human C1 inhibitor. For hereditary angiodema. 
In phase 3 trials. 
 Rabbit-derived  RhC1INH. A potential treatment for angioedema, has received a fast track 
designation for review by the U.S. Food and Drug Administration. 
The Pharming drug candidate, rhC1INH, is a treatment for hereditary 
angioedema, which causes painful and potentially life-threatening 
swelling of the body’s soft tissues. 
(Pharming produces therapeutic proteins in the milk of genetically 
modified animals and a fast track status provides an expedited review 
process for products used for life-threatening diseases with limited 
treatment options.) 
 Transgenic animals Rhucin. Is intended to treat hereditary angioedema, a disease characterised by 
the painful, and sometimes fatal, swelling of soft tissues. 
Pharming Group and Baxter 
Healthcare Corporation  
 
Rabbit-milk Derived recombinant human C1 
inhibitor. 
To treat patients with hereditary angioedema who exhibit C1 inhibitor 
deficiency. 
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Company Animal Drug Comments 
Pharming Group and Genzyme Rabbits milk Human -glucosidase to treat infants 
with Pompe’s disease, which results 
from a genetic deficiency in this 
enzyme. 
Enzyme produced in rabbits milk was well-tolerated and showed 
clinical benefit in treated patients. 
PPL Therapeutics Sheep Alpha-1 antitrypsin. 
Lipase. 
 
 Rabbits Lipase.  
TranXenoGen Chicken eggs Human proteins.  Company is essentially in liquidation, seeking to out-license patents 
and other assets. 
UC Davis  
 
Genetically 
engineered goats to 
produce an 
antibacterial milk 
Lysozyme. Could eventually protect children from diarrheal diseases. 
Lysozyme is an important antibacterial enzyme in human breast milk 
that is substantially lacking in the milk of diary animals. 
US Transgenics Plasma products  Now defunct. 
Virage Chickens Recombinant proteins.  
Vivalis Chickens Recombinant proteins.  
Sources: (Cline, 2006; Collins, 2003; Colorado State University, n.d.; Daniell et al., 2001; DOR BioPharma Inc, 2006; Elbehri, 2005; Fischer & Emans, 2000; Fischer et al., 2004; Fox, 2006; 
GianCarlo, 2006; Giddings et al., 2000; Keefer, 2004; Larrick & Thomas, 2001; Leake, 2006; Leske, 2006; Ma et al., 2003; Schoebi, 2005; Tae-Gyu, 2006; Thiel, 2004; Wisner, 2005) 
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